Radiolabelled Iododeoxyuridine for Experimental Targeted Radiotherapy of Glioma by Neshasteh-Riz, Ali
Radiolabelled iododeoxyuridine for experimental targeted 
radiotherapy of glioma
ALI NESHASTEH-RIZ 
BSc., MSc.
A thesis presented for the degree of Doctor of Philosophy, 
Faculty of Medicine, University of Glasgow
Department of Clinical Physics and Bio-engineering & 
Department of Radiation Oncology, CRC Beatson Laboratories 
University of Glasgow
July 1997
ProQuest Number: 13832094
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13832094
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
\ W > ^  i o ° i9 ^
C e r s ^  I
' ' . {' 
GLASGOW ! 
UNIVSftSriY  
LIBRARY
ABSTRACT
Gliomas are the most common primary tumours arising in the human brain. The most 
malignant glioma, the glioblastoma, represents 5000 new cases per year in the United 
States. Despite surgery, chemotherapy, and radiotherapy, glioblastomas are almost always 
fatal, with a median survival of less than a year and a 5-year survival rate of 5.5% or less. 
After treatment, recurrent disease often occurs locally; systemic metastases are rare. 
Neurologic dysfunction and death are from local growth. No therapeutic modality has 
substantially changed the outcome of patients with glioblastoma. Therefore, we have 
explored a novel form of treatment: targeted radiotherapy using radioiododeoxyuridine, a 
thymidine analogue that is intended to destroy glioma cells yet spare normal brain tissue. 
Radiolabelled IUdR is an appropriate targeting vehicle for the delivery of radiation to 
proliferating tumour target tissue. This study included an investigation of the most 
suitable radioisotopes to conjugate to IUdR.
Heterogeneous proliferative activity of glioma cells (ie non-cycling cells) is one of the 
main barriers to the therapeutic potential of radiolabelled IUdR. Therefore, an important 
part of this work was obtaining appropriate models for the study of human gliomas in 
vitro. We thus employed spheroids derived from UVW, SB 18 and U251 glioma cell 
lines, as well as cells in exponential monolayer growth and plateau phase for this 
evaluation. Multicellular spheroids grown from established cell lines have been shown 
to have growth kinetics similar to in vivo tumours. As with the clinical situation, in the 
spheroid model there is an increase in the number of resting cells as the size of the mass 
enlarges and also there are nonproliferating cells and necrosis in the more central hypoxic 
area. The UVW cell line was chosen because of its capability to grow as very large and 
regularly shaped spheroids. The karyotype anlaysis of UVW cell line revealed a highly
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aneuploid cell line.
This cell line was also very radioresistant in both monolayer and spheroid cultures as 
determined by external beam radiation experiments. The survival fraction values obtained 
at 2 Gy (SF2) were 0.55 for exponential monolayer cells and 0.83-0.93 for spheroids 
gained from clonogenic assay and growth delay experiments respectively. These values 
place this cell line at the radioresistant part of the spectrum of human cell line 
radiosensitivity.
We assessed the effect of proliferative heterogeneity on the uptake of non-radiolabelled 
IUdR by studying different sizes of UVW human glioma spheroids and monolayer cell 
cultures in exponential and plateau phases, in conjunction with flow cytometry. The 
results of the study confirm that there is an inverse relationship between the proportion of 
cycling cells and spheroid diameter. In monolayer cultures more than 95% of 
exponentially growing cells and 62% of plateau phase cells were labelled with IUdR after 
one doubling time. However, the labelling index in the small spheroids (100-200pm) was 
approximately 76% and 28% for large spheroids (700-1000pm) after one volume doubling 
time incubation (52 hours). The proportion of cells that incorporate IUdR is small and 
large sizes of spheroids increased with increasing the period of incubation with IUdR from 
one to four volume doubling times.
The effect of spheroid size and incubation time on labelling index was also evaluated in 
conjunction with autoradiography and Ki67 immunostaining. In these experiments nuclear 
incorporation of [125I]IUdR decreased markedly with increasing size of spheroid. The 
distribution of IUdR was uniform throughout small spheroids (<200pm), while the 
concentration of IUdR occured predominantly in the peripheral cells of larger spheroids.
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Radiopharmaceutical uptake corresponded closely to the regions of cell cycling as indicated 
by staining for the nuclear antigen Ki67. The IUdR uptake enhancement occurred by 
increasing the incubation time from 52 hours to 104 hours. It was concluded that a single 
injection of radioiodinated IUdR would be insufficient to sterillise all of the malignant 
cells. Therefore, to achieve maximal therapeutic benefit IUdR should be administered 
either by multiple injections or by slow release from polymers or slow-pump delivery.
As a possible approach to overcome this barrier of proliferation heterogeneity, the 
toxicities of three radioiodoanalogues of IUdR, [123I]IUdR, [125I]IUdR and [131I]IUdR were 
compared, using the human glioma cell line UVW, cultured as monolayers in exponential 
and plateau phase of growth and as multicellular spheroids using a clonogenic end point.
Both 125I and 123I are veiy short range Auger emitters while 13,I is a p-emitter which will 
provide some 'cross fire' irradiation between cells. The experiments showed that 
[125I]IUdR (concentration resulting in 37% survival (C37) = 2.36 kBq/ml) was a more 
effective eradicator of clonogens in monolayers treated in exponential growth phase than 
[I23I]IUdR and [131I]IUdR (C37 = 9.75 and 18.9 kBq/ml) respectively, whereas plateau phase 
monolayer cultures were marginally more susceptible to treatment with [123I]IUdR and 
[125I]IUdR (40% clonogenic survival) than [,3,I]IUdR (60% clonogenic survival). In 
glioma spheroids both [125I]IUdR and [123I]IUdR, were again more effective than [131I]IUdR 
at concentration up to and including 20 kBq/ml. However, at concentrations of 40 kBq/ml 
and higher, [131I]IUdR was superior in killing relative to the other isotopes, resulting in 
lower survival for [,31I]IUdR than [123I]IUdR and [125I]IUdR. The clonogenic survival 
values at 100 kBq/ml were 13%, 45% and 28% for [131I]IUdR, [123I]IUdR and [125I]IUdR 
respectively. In conclusion, only cells which were in S phase during the period of 
incubation with radiopharmaceutical, were killed by IUdR conjugated Auger electron 
emitters (123I and 125I), whereas [131I]IUdR at higher concentration had superior toxicity to
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clonogenic cells in spheroids due to cross-fire P-irradiation on G0 cells. These findings 
suggest that a combination of [131I]IUdR and [125I]IUdR or [123I]IUdR might be more 
effective than [125I]IUdR or [123I]IUdR alone for the treatment of residual glioma. Another 
therapeutic strategy may be based on combination of Auger emitters and a-emitter 
radioisotopes like 211 At in the form of [211At]AUdR and [125I]IUdR for eliminating 
untargeted cells.
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1.1 Historical Background
Malignant gliomas comprise more than 40% of central nervous system malignancies and 
are associated with a very poor prognosis (MacDonald, 1994). They also account for 
approximately 20% of all paediatric neoplasms of which approximately two-thirds are 
infratentorial. Gliomas present a supreme challenge to local modes of therapy (Kramer, 
1975). In 1966, Bouchard reported that growth and extension of primary intracranial 
tumours is essentially a regional and localized neoplastic process (Bouchard, 1966). 
Although this tumour does not metastasise to distant sites, it undergoes diffuse local spread 
within the brain. Surgical resection with a generous margin of adjacent normal tissue is 
rarely feasible (Kramer et al., 1972).
The percentage of patients cured by surgery alone has not increased significantly despite 
the development of new diagnostic tools, improved surgical and anaesthetic techniques and 
earlier referral of patients for definitive treatment. As radiation therapy has improved, its 
role has expanded in the treatment of many types of central nervous system neoplasms 
(Rasmussen et al., 1966).
Shortly after the discovery of X-rays and of radioactivity, at the end of the 19th century, 
radiotherapy was applied to the treatment of brain tumours. It was the first modality to 
make a significant difference to the survival of patients with malignant intracranial lesions 
(Walker et al., 1978). In 1921, Ewing predicted the radiosensitivity of various brain 
tumours based on several histological criteria (Ewing, 1921). However, we nowadays 
consider that histological features may predict the speed of response to radiotherapy, rather 
than the magnitude of cell kill. Nordentoft (1922) reported the treatment with radiation 
therapy of nineteen clinically diagnosed brain tumours, nine of which regressed and ten
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failed to respond. He concluded that those who failed to respond were incorrectly 
diagnosed.
In 1977, Sheline examined a number of published studies which compared the results of 
surgery alone to the use of surgery and postoperative radiation therapy (Sheline, 1977). 
He documented a benefit for the addition of radiation therapy in grade III tumours and a 
benefit in grade IV tumours for up to 4 years. Subsequently, it was demonstrated by a 
prospective randomized comparison, that an unequivocal benefit was derived from the 
addition of postoperative radiation therapy relative to surgical removal alone (Walker et 
al., 1978).
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1.2 Classification of gliomas
Glia are the most numerous cells in the human brain, and comprise astrocytes, 
oligodendrocytes and ependymal cells. Astrocytes perform many essential functions, 
including participation in neuronal conduction and response to injury. Oligodendrocytes 
produce the myelin sheaths that facilitate conduction of neuronal impulses, while 
ependymal cells line the ventricles of the brain, and specialized ependymal cells in the 
choroid plexus regulate cerebrospinal fluid production. Malignant gliomas are divided 
into three histopathological grades. These include low grade astrocytoma (World Health 
Organization grade II), anaplastic astrocytoma (grade III) and GB (glioblastoma) (grade 
IV) (Kleihues et al., 1993). The most malignant form (GB), is thought to arise either de 
novo or secondarily from lower-grade glioma. The designation 'multiforme', used in older 
nomenclature, refers to the pathological heterogeneity characteristic of this tumour (Table 
1.1). Secondary GBs characteristically occur in younger adults and can develop years 
after an initial diagnosis of a low-grade tumour. Alternatively, GB might occur in a so- 
called de novo form, where there is no clear history of a lower-grade precursor lesion, a 
scenario typically occurring in older adults (Morantz, 1995). Of the malignant gliomas 
that affect adults, the most prevalent are the astrocytomas and GB which greatly 
outnumber all other types, accounting for at least 70% of cases. The less common 
oligodendrogliomas and oligoastrocytomas each represent about 5 to 15% of the total 
number of cases. The prognosis in malignant glioma correlates with the patient's age and 
performance status, tumour grade and tumour type but in general, younger, fitter patients 
with lower-grade, non-astrocytic tumours have somewhat better prognoses. However, the 
lower-grade tumours display a remarkable tendency to undergo malignant transformation 
(Morantz, 1995) and younger patients with lower-grade tumours will frequently represent 
with higher-grade tumours with rapidly fatal consequences. For these reasons, there has
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been interest in elucidating the biological basis of malignant progression in gliomas 
(Leenstra et al., 1994).
It is worth noting however, that any histologic grading system will suffer inaccuracies if 
insufficient or unrepresentative biopsy material is submitted for evaluation. This is 
especially true for gliomas, which have considerable intratumoral heterogeneity (Taratuto 
et al., 1991; Paulus and Peiffer, 1989).
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Table 1.1 WHO histological typing of CNS tumours (Kleihues et al., 1993)
Tumours of neuroepithelial tissue
Astrocytic tumours 
Astrocytoma 
Variants: Fibrillary
Protoplasmic 
Gemistocytic 
Anaplastic (malignant) astrocytoma 
Glioblastoma
Variants: Giant cell glioblastoma 
Gliosarcoma 
Pilocytic astrocytoma 
Pleomorphic xanthoastrocytoma 
Subepedymal giant cell astrocytoma
Oligodendroglial tumours 
Oligodendroglioma 
Anaplastic (malignant) 
oligodendroglioma
Ependymal tumours 
Ependymoma 
Variants: Cellular 
Papillary 
Clear cell 
Anaplastic (malignant) ependymoma 
Myxopapillary ependymoma 
Subepenymoma
Mixed gliomas 
Oligo-astrocytoma 
Anaplastic (malignant)
Oligo-astrocytoma
Others
Choroid plexus tumours 
Choroid plexus papilloma 
Choroid plexus carcinoma
Neuroepithelial tumours o f  uncertain origin
Astroblastoma
Polar spongioblastoma
Gliomatosis cerebri
Neuronal and mixed neuronal-glial tumours 
Gangliocytoma
Dysplastic gangliocytoma o f  cerebellum  
Desmoplastic infantile ganglioglioma 
Dysembryoplastic neuroepithelial tumour 
Ganglioma
Anaplastic (malignant) ganglioma 
Central neurocytoma
Pineal parenchymal tumours
Pineocytoma
Pineoblastoma
M ixed/ transitional pineal tumours
Embryonal tumours
1. Medulloepithelioma
2. Neuroblastoma 
Variant:ganglioneuroblastoma
3. Ependymoblastoma
4. Retinoblastoma
5. Primitive neuroectodermal tumours (PNET) 
with multipotential differentiation-neuronal, 
astrocytic, ependymal, muscle, melanocytic,
etc.
a. Medulloblastoma
Variants: desmoplastic, medullomyoblastoma, 
melanocytic medulloblastoma
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1.3 Epidemiology of glioma
1.3.1 Incidence
Primary brain tumours, of which about 40% are gliomas, constitute 1-2% of all human 
tumours (Codd and Kurland, 1985; Laerum et al., 1978). The most malignant glioma, 
glioblastoma, represents 29% of all primary brain tumours or 5000 new cases per year in 
the United States (Mahaley et al., 1989). All gliomas are all malignant to some extent and 
about 50% fall into the WHO categories anaplastic astrocytoma and glioblastoma of grade 
III or IV. Table 1.2 shows the WHO grading system of CNS tumours (Kleihues et al.,
1993).
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Table 1.2 World Health (1993) Organization grading system (malignancy scale) of CNS
tumours
Tumour Group 
Astrocytic tumours
Oligodendrogliomas 
Oligo-astrocytomas 
Ependymal tumours
Choroid plexus- tumours
Neuronal/glial tumours
Pineal tumours
Embryonal tumours
Cranial & spinal nerve 
tumours
Meningeal tumours
Tmour Type Grade Grade Grade Grade
I II III IV
Subependymal- *
giant cell
Pilocytic *
Low grade *
Pleomorphic * *
xanthoastrocytoma
Anaplastic *
Glioblastoma *
Low grade 
Anaplastic
Low grade 
Anaplastic
Subependymoma 
Myxopapillary 
Low grade 
Anaplastic
Papilloma
Carcinoma
Gangliocytoma
Ganglioglioma
Desmoplastic-infantile
ganglioma
Dysem bryopl astic
neuroepithelial tumour
Central neurocytoma
Pineocytoma 
Pineocytoma / 
pineoblastoma 
Pineoblastoma
Medullobastoma 
Other PNETs 
Medulloepithelioma 
Neuroblastoma 
Ependymoblastoma
Schwannoma 
Malignant peripheral 
nerve sheath tumour
Meningioma 
Atypical meningioma 
Papillary mengioma 
Hemangiopericytoma 
Anaplastic- 
meningioma
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1.3.2 Mortality
The death rate for intracranial tumours is similar in most countries which produce 
mortality statistics, and ranges between 3.2-5.6 per 100,000 of population (Muir et al., 
1994). Table 3.1 shows the comparison of mortality rates in 1960 and 1985.
1.3.3 Age and sex distribution
Glioblastoma is a disease which affects children and adults of all ages with greater 
incidence in late middle age (Komblith et al., 1987). The overall incidence of 
primary brain and central nervous system cancer ranges from six to sixteen per
100,000 (Polednak, 1991) and the age-adjusted incidence of primary brain tumours is 
rapidly increasing in the United States, especially in the elderly and has more than 
doubled over the past two decades (Desmeules et al., 1992). It was estimated that 
17,500 Americans would develop malignant brain tumours in 1994 (Boring et al.,
1994). The Connecticut Tumour Registry noted a significant increase in brain tumour 
incidence in age groups from 65 to 69 years and 80 to 84 years between the periods 
1965 to 1969 and 1985 to 1988 (Polendak, 1991). In a study in Lothian Region in 
south-east Scotland in 1989 to 1990, among 106 patients, 60 (57%) were of working 
age (15 to 64 years). The average annual incidence of cerebral glioma in this age 
range was 5.9 per 100,000 per year. Overall it was reported that cerebral glioma will 
affect approximately 2100 people of working age in the UK every year (Grant et al., 
1996).
The reason for the increase has not been determined, but dental radiographs and 
therapeutic radiation in childhood might be associated with slightly higher incidence
1 0
of brain tumours (Ryan et al., 1992). Some studies have also reported an increased 
incidence of primary brain tumours in individuals extensively exposed to 
electromagnetic fields (Feychting and Ahlbom, 1992). Others suggested etiological 
factors associated with increased CNS tumour risk include industrial chemicals, head 
injury and diet in childhood (Giles and Gonzales, 1995).
Brain tumours tend to occur most frequently at two distinct periods of life: in childhood 
and in late middle age. Posterior fossa tumours are commoner in children (e.g. 
medulloblastomas and cerebellar astrocytomas) whereas supratentorial hemisphere 
tumours are most common in adults (e.g. malignant astrocytomas). There is some 
evidence to suggest an unequal sex distribution of some tumour types. Glioblastomas 
and medulloblastomas being more common in males than females (1.5-2.3 :1), whilst 
meningiomas are more common in females (Laerum et al., 1978).
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1960 1985
Location Male Female Male Female
Canada 4.3 3.0 4.9 3.3
Singapore _ _ 1.8 1.1
Israel _ _ 3.2 2.4
Finland 3.2 2.2 4.1 3.5
Norway 4.5 3.2 5.1 3.3
Sweden 3.6 2.5 4.5 3.5
Switzerland 4.1 2.6 4.9 3.1
UK, Scotland 4.2 2.7 4.6 3.2
New Zealand 5.0 3.3 5.4 3.7
USA 3.9 2.6 4.1 2.8
Table 3.1 Average annual, age-adjusted, mortality rates per 100, 000 for malignant 
neoplasms of brain in selected countries, by sex for 1960 and 1985 (Muir et al., 1994).
12
1.4 Genetic factors
Over the past several years, some of the molecular abnormalities associated with primary 
brain tumours have been elucidated, but it is still unclear which genetic aberrations are the 
rate-limiting steps that lead to neoplastic transformation and progression to various 
malignant stages. The application of molecular biological techniques to the investigation 
of gliomas has greatly increased our understanding of changes that lead to their creation. 
This tumorigenic process involves an interplay between two classes of genes: oncogenes and 
tumour suppressor genes. It is believed that these genes exert a balance control on cell 
growth (Bigner et al., 1988; Weingerg, 1989). Cells can receive an exaggerated impulse 
to grow and divide either from oncogene activation or from tumour suppressor gene 
inactivation.
Various chromosomal abnormalities have been described in gliomas, most of which are 
associated with the most malignant form, glioblastoma multiforme. These include gain of 
chromosome 7 and loss of chromosomes 9p, lOp, l ip  , 13p, 17p, or 22. The tumour- 
suppressor genep53 which is located on 17p (Fults et al., 1992a) is discussed below. Also 
in the low-grade gliomas, including oligodendrogliomas and mixed oligodendroglioma, 
double-minute chromosomes occur less frequently than in malignant gliomas.
1.4.1 The v53 gene
The p53 gene is located on the short arm of chromosome 17 and is composed of 11 exons 
that encode a 2.2 to 2.5-kb messenger RNA, producing a 53,000-D protein (Fults et al., 
1992b). The protein has an acidic N terminal that forms an a  helical structure and a basic 
C terminal capable of binding DNA. The encoded protein of the wild-type p53 gene has
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been shown to function in a wide variety of biological processes including the suppression 
of cell transformation, but certain gene mutations result in loss of this function and increase 
the transformation potential of cells. It has been suggested that the p53 gene acts as the 
'guardian of the genome', repairing mutagenic alterations or mediating cell death (Lane, 
1992). The wild-type p53 protein may be involved in inhibition of DNA synthesis and 
Gj phase arrest after cellular DNA damage (Kuerbitz et al., 1992). Such cell-cycle delays 
(checkpoints) provide opportunities for DNA repair before replication or segregation of the 
affected chromosomes (Hartwell and Weinert, 1989). Therefore, alterations of the p53 
gene are thought to cause genomic instability that may induce other genetic changes. In 
addition to cell cycle arrest, DNA damage may also induce apoptosis (programmed cell 
death) in multicellular organisms, thus eliminating cells in which damage is beyond repair, 
protecting the host organism at the expense of the individual cell (Enoch and Norbury,
1995). It has been suggested that in some cell types such as lymphocytes and bone 
marrow cells, p53 is important for triggering both apoptosis and Gj arrest following 
irradiation but that in others, such as fibroblasts, it is important only in initiating G, block 
(Slichenmyer et al., 1993). In lymphocytes, loss of wild type p53 may lead to a decreased 
capacity for apoptosis which is manifested as increased radioresistance. However, in 
fibroblasts in which the p53 signal is not important for apoptosis, loss of wildtype p53 
function may not affect radiosensitivity. Mutations of the p53 gene occur in many diverse 
human tumour types, including gliomas. Loss of heterozygosity (LOH), a hallmark of loss 
of tumour suppressor gene activity, and the presence of mutations in p53 have been 
confirmed in astrocytomas and anaplastic astrocytomas at a similar rate to that for 
glioblastomas (Von Deimling, 1992a). Such alterations are rare in low-grade gliomas but 
appear to occur with the same frequency in anaplastic astrocytomas and glioblastomas, 
indicating that they may signal the transition from low-grade to malignant forms (Fults et 
al., 1992b). Some studies have indicated that p53 may be involved in tumour progression
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because it is more common in gliobastomas than in anaplastic astrocytomas (Chung et al., 
1991). Investigation of p53 mutations in four glioma patients before and after malignant 
transformation showed mutations only in tumour recurrence (Hayashi et al., 1991). All 
p53 mutations found so far in gliomas occur in exons 4 to 8, which represent highly 
conserved regions of the gene. The overall p53 mutation frequency has been reported to 
be 37% in gliomas that retain both 17p alleles but 64% in tumours that lose a single allele 
of chromosome 17p (Frankie et al., 1992).
It appears that in low grade astrocytomas (grade II), mutations of the p53 tumour suppressor 
gene with or without LOH on chromosome 17p, constitute the earliest detectable genetic 
alteration in diffusely infiltrating astrocytomas (Ohgaki et al., 1993), although isolated cases 
with LOH on chromosomes 13 and 22 have also been reported (James et al., 1988). 
Anaplastic astrocytomas (grade III) often develop over the course of several years from low 
grade astrocytomas, but may also arise de novo, that is without clinical or histopathological 
evidence of a preceding low grade glioma. In addition, more than 40% of anaplastic 
astrocytomas show LOH on chromosome 19p (Von Deimling et al., 1992b) and more than 
70% of glioblastomas have LOH on chromosome 10 (Ransom et al., 1992).
Oligodendrogliomas and oligoastrocytomas are less common, and are not as well 
characterized as astrocytomas. Oncogene amplification has only rarely been noted in 
oligodendroglial tumours (Reifenberger et al., 1994). Most reports have emphasized that 
allelic losses in oligodendrogliomas and oligoastrocytomas occur preferentially on 
chromosomes lp and 19p, affecting 40 to 80% of these tumour types (Bello et al.,1994) 
Due to the frequent loss of these loci in low-grade, as well as anaplastic, 
oligodendriogliomas and oligoastrocytomas, the putative lp and 19p tumour suppressor 
genes are probably important early in oligodendroglial tumorigenesis. In contrast to
15
diffusely infiltrating astrocytomas, non-astrocytic brain tumours and pilocytic astrocytomas 
do not or very rarely contain p53 mutations, thus suggesting a different genetic basis for 
these CNS neoplasms (Ohgaki et al., 1991).
1.4.2 Gene amplification and oncogene expression
Several families of oncogenes may be involved in malignant glioma development. 
Many of these encode receptors for factors believed to be involved in glioma 
tumorigenesis (Maruno et al., 1991; Westphal and Herrmann 1989) such as epidermal 
growth factor (EGF), platelet derived growth factor (PDGF), insulin growth factor 
(IGF-1) and fibroblast growth factor (FGF) which have structural homologies (Cooper 
et al., 1991). Abnormalities of the epidermal growth factor receptor (EGFR) gene, 
including overexpression, amplification, and rearrangement, have been shown to occur 
frequently in glioblastoma (Ekstrand et al., 1992). The EGFR gene is located on 
chromosome 7 and encodes a transmembrane receptor protein with tyrosine kinase 
activity that becomes active upon receptor stimulation (Cooper et al., 1991). This 
would be expected to increase protein phosphorylation and, in turn, cell division. The 
loss of chromosome 10 has also been directly correlated with amplification of the 
EGFR gene (Von Deimling et al., 1992c).
In addition to EGFR gene amplification, gene rearrangement and altered expression are 
now being investigated in glioblastoma (Wong et al., 1992). Rearrangements and 
deletions on the EGFR gene in malignant glioma result in defects in the normal 
extracytoplasmic domain of the receptor and thus abnormal binding of its ligands 
(Humphrey et al., 1990). The amplified gene shows frequent deletions, including 
abnormal regions at both the 3* and 5' ends (Ekstrand et al., 1992). These alterations
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may produce tumour-specific proteins that have biological or functional significance. 
EGFR amplification has been found in 33% of all grades of astrocytomas. Patients 
with gene amplification had worse prognosis than did those without amplification, 
indicating that amplification may be a significant prognostic factor (Hurtt et al., 1992). 
In a study of 103 cases using immunohistochemical staining for EGFR, the authors 
found heterogeneous labelling of tumour cell cytoplasm in 37% of glioblastomas but 
in no other grade of astrocytomas (Agosti et al., 1992). The specific association of 
EGFR overexpression with glioblastoma may be useful in histochemically 
differentiating these tumours from anaplastic astrocytomas when the biopsy tissue is 
limited and nonrepresentative (Agosti et al., 1992).
From the above studies it can be concluded that in gliomas, which are the most 
common cerebral neoplasms, loss of p53 gene function appears to be an early event 
associated with malignant transformation and progression. Loss of genetic information 
from chromosome 9p is common in anaplastic astrocytomas. Furthermore, p53 
mutations, loss of heterozygosity on chromosome 10 and amplification of EGFR gene 
are events associated with progression of anaplastic astrocytoma to the most malignant 
form of glioma-glioblastoma. Less well-defined abnormalities are associated with 
other primary brain tumours such as oligodendrogliomas, ependymomas, 
medulloblastomas and meningiomas.
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1.5 Treatment
Malignant gliomas constitute the bulk of the intrinsic intraparenchymal tumours of both 
the brain and spinal cord which occur either as single or multifocal lesions. They rarely 
metastasize outside the CNS. These tumours, which arise from distinct types of glial 
cells, are the most difficult to treat. Regardless of the location of the malignant glioma, 
the prognosis has not changed greatly in the last 15 years (Bleehan and Stenning, 1991). 
It is not firmly established at present if treatment of the low-grade astrocytomas improves 
survival. Despite optimal treatment with surgery, radiotherapy and chemotherapy, median 
survival is approximately 6-8 years for low-grade gliomas, 3 years for anaplastic 
astrocytomas and one year for glioblastoma (Leibel et al., 1994; MacDonald, 1994). 
Survival is also influenced by histologic type and tumour grade, proliferative index, post 
surgical tumour volume, age and performance status of the patient, and type of 
chemotherapy used. Fundamental problems include the limitations of current diagnostic 
techniques such as CT and MRI to localize the extent of tumours and the difficulty of their 
total removal and effective radio sterilization. These problems stimulate urgent research 
for alternative diagnostic procedures and treatment modalities. Selective
radiopharmaceutical uptake and killing of glioma cells may improve therapy and will be 
the subject of this thesis.
1.5.1 Surgery in the treatment of malignant glioma
The first surgical removal of glioma was done by Rickman Godlee over 100 years ago 
(Bennet and Godlee, 1884). The value and role of surgery in patients with glioma 
remain contentious (Kreth et al., 1993). Surgical management is directed towards two 
goals. Firstly, to confirm the histological diagnosis and secondly to achieve tumour 
debulking. Internal decompression or near complete surgical extirpation of the tumour
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produce more prolonged relief from the effects of tumour bulk and allow further treatment 
to be more effective. Because of the location within the brain and their diffuse mode of 
local spread, complete surgical excision can not be achieved.
The diagnosis is confirmed by biopsy, guided either by intuition if the tumour is large 
enough (although this approach is accompanied by significant mortality), or by a 
stereotactic technique. A surgical reduction of at least 90% of tumour volume, (more than 
1 log of cell kill) is required for a measurable increase in survival. Patients with 
malignant glioma rarely survive more than three months after treatment by burr hole 
biopsy or external decompression. Table 1.4 gives a summary of the published results 
of such surgery covering the period 1937 to 1974.
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Chapter 2
The radiobiology of glioma cells in culture
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2.1 In vitro cell biology of human glioma
In vitro models have played an important role in studies of brain tumour biology and 
experimental therapy (Ponten and Macintyre., 1968; Rosenblum et al., 1975; Freshney, 
1980; Laerum et al., 1985). Many brain tumours are capable of limited growth in 
vitro (Russell and Bland, 1933) and several specific phenotypic properties of cultures 
from human gliomas may be associated with the malignant origin of the cells. It was 
first established by Westermark (1973) and others (Maunoury, 1977; Ponten and 
Westermark, 1978) that glioma cultures grown as continuous cell lines would reach 
a higher saturation density in culture than finite cell lines derived from normal brain. 
About 80% of glioma biopsies can be grown in short-term culture and about 40% give 
rise to established cell lines (Westermark et al., 1973). In contrast, although 50% of 
biopsy samples from medullablastoma will grow in short-term culture, few (less than 
1%) will establish in long-term culture (Freshney, 1980; Hill, 1985; Bloom et al., 
1986).
The Courtenay soft agar system has been used to grow colonies from brain tumours 
(Deacon et al., 1985). Soft agar is used to suppress the growth of connective tissue cells 
and also prevents migration of cells between adjacent colonies. Using a low concentration 
of oxygen in the gas phase allows approximate, physiological, oxygen tension in the 
medium and the addition of rat red blood cells (RBC) to the culture medium supplies labile 
growth factors (Courtenay, 1976; Courtenay and Mills, 1978).
Brain tumours have also been cultured as multicellular spheroids in suspension culture. 
In these cultures, brain tumour cells are able to reaggregate and form complex histiotypic 
patterns which show characteristics of their tissue of origin (Schwachofer et al., 1989).
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2.1.1 Karyotypic abnormalities
Karyotypic heterogeneity of glioma cell lines is common, with the number of 
chromosomes per cell ranging from 37 to over 208. Karyotype analysis often shows 
aneuploidy with different modal numbers in various glioma cell lines and instability in the 
stem-line (Westermark et al., 1973; Kawamoto et al., 1979; Shapiro et al., 1981). There 
are some non-random chromosome alterations in cultured malignant glioma; in particular 
losses of chromosomes 10 and 22 and gain of chromosome 7 (Bigner et al., 1986; Rey et 
al., 1987). James et al. (1988) compared the loss of heterozygosity between grade IV and 
grade III gliomas for loci on each chromosome. They found loss of heterozygosity 
affecting chromosome 10 sequences in samples from grade IV tumours, but not in samples 
from tumours of lesser malignancy.
2.1.2 Cvtological morphology
The morphological heterogeneity of malignant glioma in situ is well known. This is 
reflected in a considerable degree of morphological heterogeneity in cultures from these 
tumours. Bigner et al. (1981) have suggested that well established cell lines can be 
classified on the basis of their morphological appearance in confluent cultures identifying 
a range of forms that he called fibroblastic, fascicular, epithelial and glial.
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2.2 Characteristics of established brain tumours cell lines
A high proportion of cultured human gliomas have been established as permanent lines 
(Manuelidis, 1969; Westermark et al., 1973). Five cell lines established from a series of 
50 human primary intracranial tumours were reported by Maunoury (1977). These 
included 4 malignant gliomas and one meningeal sarcoma. These five cell lines were 
injected subcutaneously into both flanks of athymic nude mice but only two gave rise to 
tumours. Only one of the five cell lines was occasionally positive for glial fibrillary acidic 
protein (GFAP). GFAP is a cytoskeletal protein which is considered to be a marker of 
the astrocytic lineage (Bignami et al., 1972). However, a high proportion of cell lines 
derived from human malignant glioma do not express GFAP (Kennedy et al., 1987). 
Collins (1983) has summarised the characteristics of 42 human glioma cell lines. The 
tumour types included glioblastoma, malignant glioma, astrocytoma grade III and IV, giant 
cell glioblastoma, gliosarcoma and mixed anaplastic glioma. S-100 protein and GFAP 
expression was reported in 34 of the tumours, but only 8 cell lines were positive. S-100 
protein is an acidic, calcium binding protein that is concentrated in the central nervous 
system and produced mainly by astrocytes (Donato, 1991). It was considered to be 
unique to the nervous system but it has now been found in a number of other cell types 
including cultured human melanoma cells (Gaynor et al., 1980) and skin cells (Cocchia et 
al., 1981).
Rutka et al. (1987) established and characterized five cell lines from human malignant 
gliomas. These cell lines grew both in monolayer and soft agar. The doubling time 
varied from 29-34 hours in monolayer culture. In the early-passage, cultures, only one 
cell line expressed GFAP, but lost this during serial passage apparently a common finding 
(Diserens et al., 1981; Westphal et al., 1990).
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While there is limited experimental data suggesting that high levels of expression of GFAP 
might reduce the motility of malignant astrocytes, there is no consistent evidence that loss 
of this cytoskeletal protein defines a more malignant phenotype (Duffy et al., 1982). 
Studies of GFAP positivity are summarized in Table 2.2.
Authors Number of cell lines GFAP positive cell lines
Maunoury, 1977 5 1
Collins, 1983 34 8
Rutka et al., 1987 5 1
Table 2.2 The GFAP status in established human malignant glioma cell lines.
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2.3 Growth kinetics of human brain tumours in vitro and in vivo
The principal attributes of malignant solid tumour cell populations in vivo are:
a) loss of normal growth control.
b) ability to invade and metastasise.
c) ability to induce angiogenesis.
Brain tumours have certain characteristics in common with other neoplasms. In vitro, 
some cells from malignant gliomas appear to be capable of unlimited proliferation, in 
contrast to normal adult glial cells for which the maximum number of passage is 15 
(Pertuiset et al., 1985). When the concentration of serum supplement in the culture 
medium is reduced below 5%, proliferation of normal astrocytes rapidly stops whilst 
established glioma cell lines continue to proliferate in less than 1% serum. If serum is 
removed entirely, normal glial cell proliferation is arrested in the G0/G, phase of the cell 
cycle. It has been demonstrated that glioma cells remain in G0 in the absence of serum 
derived growth factors but are readily recruited into cycle after even short (one hour) 
exposure to serum, whereas up to 12 hours incubation is required to stimulate the growth 
of normal glia (Collins, 1983). This would seem to indicate that normal glial cells need 
a large number of growth factors in serum for continued proliferation, whilst glioma cells 
do not. There is now considerable evidence for the involvement of platelet-derived 
growth factor (PDGF) and other growth factors in the growth regulation of glial and 
glioma cells. PDGF stimulates proliferation of human glial cells (Heldin et al., 1980) and 
it has been reported that glioma cells express an oncogene which codes for PDGF 
(Grinspan et al., 1994).
The proliferative activity of neoplastic cells is an exciting field for histopathological 
investigation due to the suggested correlation between cell proliferation rate and biological
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aggressiveness. Several techniques are available for evaluating cell kinetics including, 
immunostaining of cell cycle-related antigens such as Ki67 and proliferating cell nuclear 
antigen (PCNA), bromodeoxyuridine incorporation and determination of percentage of cells 
in S phase by flow cytometry (Hall and Levison, 1990).
The nuclear antigen Ki67 is perhaps the most widely used proliferation marker and is 
expressed in cell cycle phases Gt, S, G2 and mitosis but not in G0 cells. It has recently 
been characterized as a highly protease-sensitive, nonhistone protein with an apparent 
molecular weight of 395 kD (Gerdes et al., 1984; 1991). Values of Ki67 labelling indices 
parallel the degree of histologic malignancy in many tumours including GB, anaplastic 
astrocytoma, pituitary adenoma and meningioma (Louis et al., 1991 ; Shibuya et al., 1992). 
Burger et al. (1986) have found that intensity of nuclear staining of gliomas for Ki67 
corresponds with more malignant histologic appearance and faster growth characteristics.
Another immunohistochemical marker, PCNA, may have use as an index of proliferation 
rate and tumour aggressiveness (Prelich et al., 1987). PCNA expression is increased 
through Gj, is at a maximum in early S phase, declines through G2 phase, and reaches low 
levels at M phase and interphase. The monoclonal antibody PC 10 binds to the PCNA 
epitope in both frozen and formalin-fixed paraffin-embedded tissue, thus allowing 
retrospective studies (Gelb et al., 1992). PCNA indices may be modified by the action 
of growth factors (PDGF, FGF, and EGF) or other exogenous agents (Bravo and 
McDonald, 1984; Jaskulski et al., 1988). Comparisons of PCNA with Ki67 labelling 
indices in primary brain tumours indicated that PCNA may be a more specific S-phase 
marker but a less accurate index of proliferation activity than Ki67 (Allegranza et al., 
1991). However, Figge et al. (1992) reported that PCNA was not a useful prognostic 
parameter in determining survival in glioblastomas.
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Monoclonal antibodies against bromodeoxyuridine (BUdR), a thymidine analogue 
incorporated during DNA synthesis, can be used to determine the S-phase fraction in cell 
populations. Bromodeoxyuridine labelling indices can be obtained by flow cytometry.
Glioma cell proliferation in vitro and in vivo has been studied mainly by labelling with 
BUdR and Ki67. Nishizaki et al. (1989) assessed cell proliferation potential by measuring 
the labelling indices of Ki67 and BUdR in 48 brain tumours. They showed both Ki67 and 
BUdR labelling indices correlated with the degree of malignancy estimated from 
conventional histological preparations. The mean BUdR labelling index in glioblastoma 
was 9.9% and the Ki67 labelling index was 13.5%. For anaplastic astrocytoma and 
astrocytoma the BUdR labelling indices were 4.3% and 1.6% and the Ki67 labelling 
indices were 5.2% and 2.2% respectively. Hoshino et al. (1992) studied cellular growth 
kinetics by in situ double labelling with BUdR and iododeoxyuridine (IUdR) in 57 patients 
with brain tumours including 29 gliomas, 23 meningiomas and 5 miscellaneous. The 
patients received infusions of intravenous IUdR and BUdR 1-5 hours apart shortly before 
tumour removal. Excised tumour specimens were stained sequentially for BUdR and 
IUdR. The percentage of BUdR-labelled cells was determined to establish the labelling 
index, or S-phase fraction, and the ratio of cells labelled only with IUdR to cells labelled 
with BUdR or with BUdR and IUdR was determined to calculate the duration of S-phase 
(Ts) and the potential doubling time (Tpot ) of each tumour. The Tpot, is defined as the 
time within which a cell population would double its number if cell loss did not occur. 
The BUdR labelling index varied from 1% to 20%, reflecting the malignancy of each 
tumour. Ts, was 8.7±2 hours and Tpot varied from 2 days to more than one month. In 
vitro doubling times of glioma cells vary from 22 to 144 hours (Pertuiset et al., 1985). 
Perez et al. (1995) summarized available information on the IUdR labelling indices in 
xenograft models of seven well established cell lines originating from human malignant
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gliomas. The mean Tpot, Ts and labelling index were 4.9 days, 19.4 hours and 17.7% 
respectively. Several studies on the proliferation rate of brain tumours using Ki67 and 
other proliferative markers have been reported (Morimura et al., 1991; Schroder et al., 
1991; Onda et al., 1994). The percentage of Ki67 positive cells (growth fraction) tended 
to reflect the histological grade of malignancy.
2.4 The multicellular tumour spheroid model
The major objective of the present investigation is an evaluation of the effect of 
proliferative heterogeneity of tumour cells on the therapeutic potential of the cycle-specific 
agent radiolabelled IUdR. Therefore an important part of this work was the evaluation 
of the appropriateness of different in vitro glioma models. Cultures in the form of three- 
dimensional multicellular spheroids are especially useful for the study of radiation 
responses.
Experimentally induced aggregates of animal cells have been in use since the pioneering 
studies of Holtfreter (1944). Studies were performed by Moscona (1961) to assess the 
capacity of embryonic and malignant cells for reaggregation, proliferation and 
differentiation. Due to their spherical shape, the aggregates were termed multicellular 
spheroids. The structure of spheroids is similar to that of solid tumour nodules, composed 
of dividing cells close to the capillaries, adjacent non-proliferating cells and more distant 
necrotic regions (Carlsson and Nederman, 1989). The cell survival curves obtained from 
radiation experiments either with aggregates or with solid tumours were similar (Sutherland 
et al., 1970; 1971). As spheroids enlarge, the external, well-nourished cells continue to 
divide but the internal cells, lacking nutrients, often exit the cell cycle and enter G0 or non 
proliferating state (Durand, 1990). Enlargement of spheroids can also be accompanied by
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changes in ploidy (Olive et al., 1982), changes in extracellular matrix constituents (Grover 
et al., 1983), development of central necrosis (Inch, 1970), and development of hypoxia 
(Durand, 1984).
Multicellular tumour spheroids are a well-established model of prevascular microtumours 
that provide a means of studying the intratumoural distribution of therapeutic agents and 
of determining the effect of alternative schedules of administration on cellular 
incorporation. They have previously been used extensively in targeted therapy research 
to investigate diffusion gradients of alternative targeting agents (Langmuir et al., 1991; 
Mairs et al., 1991); to assess efficacies of alternative modalities (Rotmensch et al., 1994) 
and modulating agents (Langmuir and Medonca, 1992); to evaluate microdosimetry 
(Bardies et al., 1992), and to provide experimental model systems for testing hypotheses 
(Gaze et al., 1992). There are reported studies using glioma spheroids. For example the 
radiosensitivity of a human glioma cell line (Gronvik et al., 1996), the relation between 
radioresponsiveness and tumour differentiation (Stuschke et al., 1993), the effect of 
leukotriene and 5-lipoxygenase inhibitors on thymidine uptake (Gati et al., 1994) and the 
penetration of thymidine and thymidine-5-triphosphate in cellular spheroids (Nederman et 
al., 1988).
Tumour spheroids represent a useful in vitro model for the study of heterogeneity with 
respect to the effects of cytotoxic drugs. This is probably representative of the 
heterogeneity in real tumours which often have irregular vascularization. There are also 
cell type-dependent differences in the response to the cytotoxic agents which parallel the 
differences seen between different types of tumours. For these reasons we employed 
spheroids derived from glioma cell lines to evaluate incorporation and efficacy of the 
proliferation specific targeting agent IUdR.
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2.5 Radiobiological studies on human tumours
Radiobiology is the study of the action of ionizing radiation on living things. There have 
been important developments in the radiobiology of human tumours in recent years. 
Exposure of cells to ionizing radiation results in molecular damage that can be expressed 
at the cellular, metabolic, or chromosomal level. The most extensively studied radiation 
effect is that of cell survival, assayed by determining the proportion of cells that can make 
colonies. The eradication of clonogenic cells is the major objective of therapeutic 
irradiation, therefore the use of such an in vitro endpoint is particularly relevant to the 
measurement of tumour response to radiation. The practical limitations of this 
experimental endpoint have become apparent due to increasing interest in measuring the 
radiosensitivity of human cells. Many normal human tissues have limited or no 
proliferative potential, and the low cloning efficiencies observed in primary tumour 
cultures are major barriers to the routine measurement of cellular radiosensitivity (Peters, 
1990). Despite the practical difficulties inherent in the clonogenic cell assay, it has 
generated most of the currently available data on mammalian cellular radiosensitivity. It 
has the advantage of allowing the measurement of cellular radiation dose-response over 
a logarithmic range. This is possible because relatively high concentrations of viable cells 
(105-106/ml) can be readily prepared from continuous cell lines.
A cell survival curve describes the relationship between the radiation dose on a linear scale 
and the proportion of clonogenic cells that survive on a log scale. Surviving fraction is 
calculated from the relationship:
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colonies counted 
Surviving fraction = _________________
cells seeded x (PE/100)
where plating efficiency (PE) of the experiment is the percentage of cells forming colonies 
in control plates. The mathematical models of radiation most commonly used to quantify 
cellular radiosensitivity are described below.
2.5.1 Single hit killing
Many different mathematical models have been proposed to define the shapes of survival 
curves. All of these are based on the concept of the random nature of energy deposition 
by radiation.
The earlier models, which are discussed in detail by Elkind and Whitmore (1967), were 
based on the idea that a specific target had to be inactivated for cells to be killed. 
According to this model the number of targets (c/N) inactivated by a small dose of 
radiation (*/D) should be proportional to the initial number of targets N and to dD, 
therefore
<7N oc N dD or <7N = - (1/D0) N dD,
where 1/D0 is a constant of proportionality and the negative sign is introduced because the 
number of active targets N decreases with increasing dose. This equation can be 
integrated to give 
N = N„ e (‘D/D0),
where N0 is the number of active targets present at zero dose. If it is assumed that cells 
contain only a single target that must be inactivated then the surviving fraction is given 
by N/N0= e '^D/D0\  This also represents the probability that any individual cell will
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survive the radiation dose D. This equation gives a straight line on a semilogarithmic plot 
representing a surviving fraction of 1 at zero dose.
If D equals D0 in the above equation, then N = N0 e*1 = 0.37 N0. Therefore D0 represents 
the dose required to reduce cell survival from N to 0.37 N which is a measure of the slope 
of the line. However, most survival curves in practice show a 'shoulder' or have 
continuously bending shapes which requires the use of more sophisticated mathematical 
models, as described below.
2.5.2 Multitarget Model
This is an alternative mathematical model which generates survival curves of characteristic 
shapes for mammalian cells in vitro. At low doses there is an initial shoulder, followed 
by a portion which becomes almost straight on a semilogarithmic plot (Figure 2.1).
The model postulates that the cell contains "n" sensitive targets each of which must be hit 
for sterilisation. Therefore the probability of inactivating one target is given by:
P, = (l-e’D/D0),
where D = dose. The probability of a cell surviving a given dose (all "n" targets hit) 
would be:
S (D) = 1- (1 - e ‘D/D0 ) ”
At high doses the survival curve predicted from this model approximates to a pure 
exponential, appearing as a straight line on a log-linear plot, with a slope of -1/D0.
The multitarget parameters are D0, n and Dq. D0 is the dose of radiation that is required, 
on the exponential part of the curve, to reduce cell survival to 37%. The extrapolation 
number (n) is the intercept when the survival curve is extrapolated back to where it cuts 
the Y axis at zero radiation dose, and the Dq is the X-axis intercept. Both Dq and n
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provide estimates of the shoulder size. These three parameters are related by the 
expression:
Loge n = Dq/D0
However, the multitarget equation has the property of zero initial slope at zero dose. 
Much mammalian cell survival data do not appear to support a zero initial slope at zero 
dose, leading to the modification of the basic multitarget equation to include a single event 
component at low doses:
S (D) =e'D/Ds [1- (l-e D/D0)]“,
where d is given dose, D0 is the reciprocal final slope, Ds is the reciprocal initial slope, 
and n the extrapolation number. However, this more sophisticated model requires 
estimation of an additional parameter (Ds).
2.5.3 Linear-quadratic model
Another approach to fitting survival curve data that is in common use is the linear- 
quadratic equation (Kellerer and Rossi, 1972). It was developed on the basis of a proposed 
relationship between dose-related induction of double strand breaks within DNA and was 
popularised by the work of Keller and Rossi (1973).
The model is described by the equation:
S (D) = e-(“ D+Pd2 >,
where S (D) is the survival fraction after a dose D, and the exponential component (a) 
and the bending component (p) are constants. The components of cell killing that are 
proportional to dose and to the square of the dose are equal when 
aD = P D2 or D = a/p
The a /p  ratio represents the radiation dose at which the cell kill achieved by a  and p 
events is equal. As a ratio its numerical value is independent of those obtained for both
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a  and p. Human cells of high radiosensitivity are usually observed to have a/p  ratios of 
greater than 8Gy, whilst only the most resistant cells have values of less than 5Gy 
(Williams et al., 1985). It is believed that recovery from radiation damage affects only 
the P-component (Peacock, 1988). For instance, when the dose rate is lowered the 
survival curve becomes shallower and straightens, until it appears to coincide with the 
linear component of the acute curve (Steel et al., 1986) (Figure 2.2). Therefore it may 
be appropriate, to regard the linear portion as a component of non-recoverable damage 
(Steel and Peacock, 1989).
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Figure 2.1 Typical survival curves for mammalian cells exposed to radiation. The 
fraction of surviving cells is plotted on a logarithmic scale against dose on a linear scale. 
The curve is characterised by two parameters; the 37% dose slope, D0, of the straight 
portion and the extrapolation number, n, which is measured of the width of the initial 
shoulder. Alternatively, the width of the shoulder may be specified in terms of the 
quasithreshold dose. Dq, which is the dose at which the extrapolated straight portion of 
the dose-response curve cuts the dose axis.
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Figure 2.2 Form of the linear-quadratic survival equation. The experimental data are 
fitted to a linear-quadratic function (shown on the curve). There are two components of 
cell killing: one is proportional to dose (aD), while the other is proportional to the square 
of the dose (PD2).
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2.6 Radiosensitivity of brain tumours
Glioma is one of the most radioresistant human tumours. Resistance may be caused by 
one or more factors. These include inherent cellular radiation sensitivity, efficient repair 
of radiation damage, high hypoxic fraction and rapid proliferation between fractions of 
radiation (Taghian et al., 1993). Human glioma cell lines have been available for in vitro 
studies since the late 1960s and the dependence of radiosensitivity on dose rate has been 
widely studied. This has practical significance for clinical radiotherapy. Several reviews 
documented the radioresistance of human glioma cell lines (Raaphorst et al., 1989; Taghian 
et al., 1992; Gupa et al., 1996).
In 1981 Fertil and Malaise published the results of their re-analysis of published human 
cell survival curves. Their review led to the use of the surviving fraction at 2Gy (SF2) 
as the best way of describing radiosensitivity among human cell lines. Deacon et al. 
(1984), described five categories of clinical radioresponsiveness, ranging from the most 
responsive (Group A) to the least responsive (Group E). Gliomas were placed in group 
E, whose average SF2 was 0.52. A good correlation was seen between cellular 
radiosensitivity (SF2 value) and category (A-E) of clinical radioresponsiveness. The in 
vitro radiation sensitivity of different human glioma cell lines has been measured using 
colony formation as the end-point of cell viability. The survival curve parameters (SF2, 
a , (3, D0, n) have been determined for single dose irradiation of exponential phase cells by 
different research groups and are summarised in table 2.3.
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Table 2.3 In vitro cell survival curve parameters of malignant glioma cell lines.
Cell line Do n otfGv P (Gy2) s f 2 Ref
KNS-42 1.9 11.6 0.3 0.063 Masuda, 1983
U-118 1.3 8.5 Millar and
Jinks 1985
U-87 1.02 38 0.02 0.06 0.8 Raaphorst,198<
U-138 1.14 14 0.056 0.057 0.7 I f
MMC2 1.29 4.5 0.34 0.029 0.45 Taghian, 1992
A7 1.56 5.9 0.22 0.022 0.53 I I
D54MG 1.05 10.5 0.266 0.0449 0.54 f l
T98G 1.61 8.3 0.092 0.0292 0.88 f l
WF 1.92 2.3 0.32 0.012 0.47 11
IJK 2.17 6.7 0.076 0.024 0.82 Ross, 1992
CCM 1.67 8.78 0.22 0.048 0.58 I I
U-251 1.69 3.11 0.21 0.051 0.56 I I
SB-18 2.38 8.13 0.10 0.026 0.77 11
The survival curve parameters (SF2, a , p, D0, n) obtained by different research groups. 
These parameters are defined in section 2.5.3.
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Rutka et al. (1996) compared the intrinsic radiation sensitivity parameters of seven human 
soft tissue sarcoma and eight human breast carcinoma with nine human malignant glioma 
cell lines in vitro by clonogenic assays under aerobic conditions on cells in exponential 
phase of growth. The results for soft tissue sarcoma and breast carcinoma cell lines 
showed the mean surviving fraction at 2Gy about 0.39 and 0.37 respectively while it was 
0.50 for malignant glioma cell lines. They concluded that cells of sarcomas and breast 
carcinoma did not show unusual radiation resistance compared with malignant glioma and 
the success rate for radiation applied against sarcomas and breast carcinoma of comparable 
size could be similar.
The radiosensitivity of the human glioma cell line U-343MGa, growing as spheroids and 
as conventional monolayers, was the subject of a study by Gronvik et al (1996). The 
spheroids were first irradiated with 60Co photons, and the radiosensitivity was then 
analyzed in different cell layers of varying proliferative activity. High radioresistance was 
found in all cell layers and the inner, mainly quiescent cells, were as resistant as the outer 
proliferating cells. The studied glioma cells were equally radioresistant under all tested 
proliferative conditions when conventional low LET radiation was applied.
The induction and repair of DNA double-strand breaks in glioma cells were studied by 
Allalunis-Tumer et al. (1995). They used the cells of two isogenic human malignant 
glioma cell lines which vary in their SF2 values by a factor of approximately 30. M059J 
cells were radiosensitive (SF2 = 0.02) and M059K cells were radioresistant (SF2 = 0.64). 
Their experiments indicated that equivalent numbers of DNA lesions were produced by 
ionizing radiation in M059K and M059J cells but more double-strand breaks were repaired 
by 30 min in M059K cells than in M059J cells. They concluded that deficient DNA 
repair processes may be a major determinant of radiosensitivity in M059J cells.
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The split dose recovery of cells of seven early-passage glioblastoma multiforme (GB) cell 
lines and six cell lines derived from tumours of a type frequently treated successfully (two 
squamous cell carcinomas of head and neck, three breast cancers and one low-grade 
astrocytoma cell line) was studied by Taghian et al. (1993). They measured in vitro split- 
dose recovery using colony formation. Results were presented in terms of recovery ratio: 
the ratio of the mean inactivation dose of split-dose radiation to that of single-dose 
radiation. Their data showed a significantly higher recovery ratio for GB than for the 
other cell types.
The cellular response to ionising radiation is beginning to be understood at the molecular 
level. Gupa et al. (1996) studied the effect ofp53 gene on Gj-phase cell cycle checkpoint 
after radiation to test whether repair occurs in the additional time provided by p53 
activation. Two different glioma cell lines were used: U87-175.4, which carried a 
dominant-negative p53 construct and lacked an X-ray-induced G,-phase cell cycle arrest 
and U87-lux.8, which carried only wild-type p53 and demonstrated an X-ray-induced G,- 
phase cell cycle arrest. U87-lux.8 cells remained in Gr phase for 48 hours post irradiation 
while U87-175.4 accumulated to a much lesser extent in Gj-phase after irradiation. Cells 
lacking the Gr phase checkpoint showed increased survival at all radiation doses. There 
was no significant difference in repair ability nor in rate of chromosomal abberation 
between the two cell lines. They concluded that Gj-phase arrest by p53 may reduce the 
overall degree of survival by stimulating other G,-phase events.
The association between p53 gene mutation and radiosensitivity is controversial. Several 
investigators have shown that p53 mutation does not correlate with radiosensitivity and that 
the expression of mutated p53 gene increases radiosensitivity (Brachman et al., 1993; Biard
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et al., 1994). Others have argued that expression of wild-type p53 gene increases the 
susceptibility to radiation and induces apoptosis, p53 mutant lines therefore being more 
resistant (Lee and Bernstein, 1993; Mcllwrath et al., 1994). However, the radiobiology 
of human gliomas demonstrates that there are multiple biological factors involved in 
clinical radioresponsiveness.
2.6.1 Radiobiological factors
Radiation treatment of cancer is usually given as a series of daily fractions of 2Gy. The 
use of fractionated treatment arose from studies of the French radiobiologist Regaud in the 
early part of the century. He demonstrated that, with fractionated treatment to a ram's 
testes, it was possible to achieve sterilization without significant damage to the scrotal skin. 
This strategy was soon applied to the treatment of cancer. Each daily dose (fraction) kills 
the same proportion of cells, reducing cell survival to about 50%. A series of fractionated 
doses amplifies the therapeutic differential between normal tissue and tumour by several 
mechanisms, easily remembered as the 5Rs: repair of cellular injury, repopulation by 
surviving viable cells, redistribution within the division cycle, reoxygenation of the tumour, 
and radiosensitivity.
a) Repair: DNA repair is completed over a few hours but the extent of repair is not equal 
in all tissues. In general, slowly responding normal tissues such as connective tissue and 
spinal cord are capable of greater repair than malignant tissues (Withers, 1992). Thus, 
by spacing dose fractions by at least 6 hours the recovery in slowly responding normal 
tissue is greater than that in tumours.
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b) Repopulation: As cellular damage and cell death occur during the course of the
fractionated treatment, the tissue may respond with an increased rate of cell proliferation 
(Tannock, 1996). The effect of cell proliferation during treatment, known as repopulation 
or regeneration, will be to reduce the overall response. This is most important in early- 
responding normal tissues such as skin or gastro-intestinal tract or tumours whose stem 
cells are capable of rapid proliferation and will be of little consequence in late-responding 
slowly proliferating tissues like kidney or liver which do not suffer much early cell death 
and hence do not produce an early proliferative response to the radiation treatment. 
During fractionated treatment, therefore, repopulation will decrease the damage to early- 
responding normal tissue to a greater extent than late-responding normal tissue. The 
mechanisms underlying the accelerated regrowth of tumour cells are unknown, just as they 
are for normal tissue. It seems reasonable to assume that growth factors are involved, and 
that their effects may be supplemented by improved vascularization of residual tumour as 
it shrinks. Repopulation is likely to be more important toward the end of a course of 
treatment, when sufficient damage has accumulated to induce a regenerative response.
c) Redistribution'. During a course of fractionated treatment, proliferating cells may move 
from one phase of cell cycle to another between the radiation doses. This leads to two 
effects that can make the cell population more sensitive to a subsequent dose of radiation. 
First radiation typically induces a G2 block in cell cycle progression which is usually a 
sensitive phase. Secondly, some of the surviving cells will redistribute into more sensitive 
parts of the cell cycle. These effects make the whole population more sensitive to 
fractionated treatment compared to a single dose.
d) Reoxygenation: When solid tumours grow, they often outstrip their blood supply and 
acquire areas of hypoxia and necrosis. Hypoxic cells are two-to-three times as
53
radioresistant as normal cells (Withers, 1992). During the interval between dose fractions, 
killed normal cells are eliminated and the previously hypoxic cells gain better access to 
oxygen (Kallman, 1988). This process of reoxygenation limits the negative effect of 
hypoxic cells on radiocurability during fractionated radiotherapy.
e) Radiosensitivity: The study of the radiobiology of human tumours has led to the 
realization that cells from different types of tumour differ markedly in their inherent 
radiosensitivity; that is the steepness of the oxic, cell survival curve. This was shown for 
the initial part of the survival curve by Fertil and Malaise (1981). Work on a 
representative group of human tumour cell lines has confirmed that the differences in the 
oxic cell survival curves among human tumours are considerable, and large enough to 
explain the clinically observed differences in curability (Steel et al., 1987). The term 
radiosensitivity can have a number of meanings. The most direct is the steepness of the 
acute radiation survival curve. The most clinically relevant parameter is the survival 
curve at low dose rate, whose steepness may approximate to the initial slope of the acute 
cell survival curve. It is not known with certainty what factors are responsible for 
radiation sensitivity or resistance. However, DNA is considered to be the major target 
for reproductive cell death (Hagen, 1990), and differences in damage induction (Peacock 
et al., 1989) and /or repair (Ward, 1990) of DNA damage are involved.
2.6.2 Cellular recovery phenomena
The damage to mammalian cells produced by irradiation has been divided theoretically into 
three categories:
1) Lethal damage; irreversible and irreparable lesions leading to cell death.
2) Sublethal damage (SLD); non-lethal cellular injury that can be repaired, or accumulate
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with further dose to become lethal.
3) Potentially lethal damage (PLD); This damage is potentially lethal (if cells divide soon 
afterwards), but may be repaired if division is delayed. The kinetics of entry of cells into 
the cycle is therefore important and is a function of the post irradiation environment.
All three are simply operational terms, because in mammalian cells the mechanisms of 
repair and radioresistance are not fully understood. The comparative ability of human 
tumours to recover has been obtained using observation of post irradiation events at the 
DNA or chromosomal level (Steel, 1991).
2.6.3 Potentially lethal damage repair (PLD)
Repair is found in almost all tumour cell lines in which it has been sought. Potentially 
lethal damage repair (PLD), has been shown to vary considerably from one cell line to 
another (Weichselbaum and Little, 1982) and to correlate with clinical radiocurability. 
The less curable tumours show the greatest degree of PLD recovery. There is general 
agreement that PLD is repaired and the fraction of cells surviving a given dose is enhanced 
if post irradiation conditions are suboptimal for growth, so that cells do not have to attempt 
the complex process of mitosis while their chromosomes are damaged. If mitosis is 
delayed by suboptimal growth conditions, DNA damage can be repaired.
2.6.4 Sublethal damage (SLD)
This damage can be repaired under normal circumstances in hours unless additional 
sublethal damage, incurred by a second dose of radiation, is suffered. Additional radiation 
can interact with SLD to form lethal damage. Sublethal damage repair, therefore, is
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evident by the increase in survival observed when a dose of radiation is divided into two 
fractions separated by a time interval. It was observed that the surviving fraction of 
irradiated cells increased with prolongation of the split dose interval from 0 to 3 hours, 
then reaching a plateau (Elkind and Whitmore, 1967). However, SLD repair occurs 
slowly in tissues. SLD repair is most often seen in the cells whose survival curves show 
large shoulders (large n value on the multitarget model) which occurs for many glioma cell 
lines in vitro (Taghian et al., 1993).
2.7 Why are we exploring targeted radiotherapy ?
Due to fundamental problems such as limitation of current diagnostic techniques, 
localisation of malignant glioma and difficulty of total removal or effective sterilization 
of the tumour, prognosis has not changed greatly in the last 15 years. The low median 
survival motivates the search for alternative diagnostic procedures and treatment modalities 
that will allow selective killing of glioma cells. Such is the promise of targeted 
radiotherapy using radiolabelled IUdR.
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3.1 Targeted radiotherapy
One of the most generally useful modalities in oncology is ionising radiation. Though 
variation of intrinsic cellular radiosensitivity between tumours may be of major importance 
in clinical outcome, the range of variability observed is much less than for sensitivities to 
cytotoxic drugs. However, conventional radiotherapy unavoidably involves irradiation 
of normal organs and tissues. It is the vulnerability of critical normal tissues, rather than 
the existence of highly radioresistant tumour cells, which ultimately limits the effectiveness 
of radiation treatment. Targeted radiotherapy utilises a radionuclide-conjugated molecular 
vehicle which localises on the surface of malignant cells or is selectively accumulated 
within them. This enables preferential irradiation of tumour cells, relative to critical 
normal tissues. In recent years, monoclonal antibodies attracted most attention as 
potentially selective delivery vehicles, but advances in tumour and molecular biology are 
now providing a much wider choice of molecular species. Targeted radiotherapy has 
features in common with conventional radiation treatment (e.g cell kill will be governed 
by the 5Rs of radiobiology), but also important differences. These differences are related 
to specificity, uptake and penetration of the targeting agent, intracellular distribution of 
cellular receptors and the finite range of nuclear particles emitted during radionuclide 
disintegration. A wide range of radionuclides with differing physical properties is 
available for conjugation to diverse targeting agents (Table 3.1). The experimental 
investigation of targeted radiotherapy requires a three dimensional tumour model for which 
monolayer cultures are inappropriate but spheroids are more realistic.
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3.1.1 Targeting agents
For many tumours, monoclonal antibodies or antibody fragments represent the only means 
of targeting radionuclides to malignant cells (Vaeth and Meyer, 1990). Although 
monoclonal antibodies now have demonstrable usefulness in pathological diagnosis, they 
are still very limited in therapy. The evidence of therapeutic efficacy of antibody 
targeting for glioma will be discussed in following sections. However, a range of small 
molecular weight compounds with specific tumour affinities is becoming available. These 
targeting agents exploit differences in metabolism or receptor expression between tumour 
and normal cells (Table 3.1). In principle, many radionuclides are available for targeted 
radiotherapy but only 131I and 90Y have been significantly used in clinical practice. An 
important consideration is the range of the emitted particle. Even if the distribution of 
the targeting agent is uniform, small microtumours and spheroids will be underdosed if 
their size is less than the particle range, allowing much of the radiation energy to escape 
from the tumour surface (Humm, 1986). Heterogeneous uptake of targeting agents can 
also lead to underdosing of untargeted cells if there is insufficient cross-fire irradiation 
from targeted cells. This problem will be minimal when the bound radionuclide is a long 
range P-emitter like 131I or 90Y but the cross-fire dosage to surrounding normal tissue may 
then be substantial.
Conversely, strategies based upon the incorporation of ultra short range Auger electron 
emitters should reduce damage to adjacent organs but may fail to sterilise all clonogens 
if cellular uptake is not completely uniform.
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Tumour Target Targeting agent Radionuclide
Lymphoma Antigen Antibody 131I
(beta)
Neuroblastoma Noradrenaline MIBG 131I
receptor (beta)
MABG 211 At
(alpha)
Melanoma Metabolic Melanin precursor 131I, 211 At
pathway (beta, alpha)
Glioma, EGF receptor EGF 131I, 123I
squamous
carcinoma (beta, Auger)
Proliferating cells Replicating DNA IUdR 125I, 123I
(eg glioma) (Auger)
Breast cancer nuclear receptor oestradiol 125I, 123I
(Auger)
Various gene mutation oligonucleotide 125I, 123I
(Auger)
Table 3.1 Currently promising approaches to targeted radiotherapy (Mairs and Wheldon, 
1995). The type of emission are shown in the brackets.
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3.1.2 Radionuclides
Criteria for radionuclide selection for targeted radiotherapy have been discussed by several 
authors (Hofer, 1980; Wessels and Rogus, 1984; Humm, 1986; Wheldon, 1994). Table
3.2 summarizes the physical properties of some radionuclides that may have applications 
in targeted radiotherapy. In choosing a radionuclide for targeted radiotherapy 
consideration must be given to its feasibility of conjugation to the targeting vehicle, 
physical half life, particle range and its radiobiological effectiveness. In practice, clinical 
experience with targeted radiotherapy is largely reliant on P-emitters, particularly 131I and 
to a lesser extent, 90Y. An important concept is that of cross-fire, i.e. the irradiation of 
untargeted cells by radionuclides bound to neighbouring targeted cells. The particle range 
of long range p-emitters means that considerable cross-fire will occur with possible 
sterilization of untargeted cells, both neoplastic and normal.
a-emitters have high radiobiological effectiveness and short range emissions with a typical 
range of several cell diameters but are difficult to obtain and have inconveniently short half 
lives. Encouraging laboratory experience with targeted a-emitters has nevertheless been 
reported (Vaidyanathan et al., 1996; Strickland et al., 1994).
Auger emitters are radionuclides with even shorter-range emissions (1 to 3nm) and are 
of high LET quality. The potential use of Auger emitting radionuclides for cancer therapy 
has been under investigation for many years (Hofer and Hugues, 1971; Adelstein, 1993) 
but practical difficulties have delayed their clinical introduction. Auger cascades are 
generated by some radionuclides such as 123I /125I o r " mTc after decay by electron capture 
and internal conversion. Extremely low energy electrons (less than IkeV) deposit their 
energy in the vicinity of the nuclear disintegration producing 105 to 109 cGy absorbed dose 
per decay in 20-60 nm spheres (Kassis et al., 1987a; Makrigiorgos et al., 1989).
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Radionuclide Half life Emitted particles Mean range of
9 0 y  
131 j
67Cu 
199Au 
211 At 
212Bi
125 j  
123t
2.7 days 
8 days 
2.5 days 
3.1 days 
7 hours 
1 hour 
60 days 
13.2 hours
particles
p
p
p
p
a
a
Auger Electron 
Auger Electron
5 mm 
0.8 mm 
0.6 mm 
0.3 mm 
0.05 mm 
0.05 mm 
1-3 nm 
1-3 nm
Table 3.2 Physical properties of radionuclides of current interest for targeted therapy 
(Wheldon, 1994).
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The long half life of 125I (60 days) poses problems when considered in the context of 
radionuclide therapy. 123I which has a half life of 13.2 hours also emits Auger electrons. 
Approximately 11 of these electrons are emitted for each nuclear disintegration compared 
with 20 for 125I (Sastry and Rao, 1984). Experiments have shown that the decay of 125I 
in the DNA of mammalian cells leads to efficient production of DNA double-strand breaks 
(DSB) [one decay gives rise to about one DSB] (Painter et al., 1974), while 123I, on 
average, produces 0.74 DSB per decay (Makrigiorgos et al., 1992). The radiotoxicity of 
Auger-emitting radionuclides may depend on the precise molecular localization of the 
radionuclide in relation to the DNA double helix (Kassis et al., 1987a,b). For all short- 
range-emitters, heterogeneity of radionuclide deposition within the tumour is a potentially 
serious problem.
3.2. Radiobiological factors in targeted radiotherapy
In this section we address radiobiological problems likely to arise in targeted radiotherapy. 
Emphasis is placed on radiobiological considerations which are different from those 
occurring in more conventional forms of radiotherapy.
The biological effectiveness of targeted radiotherapy will depend on radiobiological factors 
as well as on the physics of dose absorption. The 5Rs of radiobiology will be involved 
to a greater or lesser extent.
Intrinsic radio sensitivity is an important factor. Due to the limited uptake of targeting 
agents at present, only tumour types with high intrinsic sensitivity will be sterilized by 
targeted radiotherapy alone. High LET agents (a  and Auger emitters) have the potential 
to over come the problem of intrinsic radioresistance.
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Repair is believed to be important because of the usually low and exponentially 
depreciating dose rate at which most of the treatment is given. In tumours for which the 
a /p  ratio exceeds 10 Gy, such as neuroblastoma, the sparing due to low-dose rate will 
probably not be great. Fowler (1990), calculated that an extra 10 to 20% dose would 
have to be given by targeted radiotherapy compared with fractionated extemal-beam 
radiotherapy. For glioma, however, with lower a/p  ratio, considerable dose-rate sparing 
could occur. It is calculated that for biological isoeffect in late-responding tissues, the 
component of targeted radiotherapy may be reduced several-fold relative to single-dose 
irradiation at high dose rate (Wheldon and O'Donoghue, 1990). However, this mostly 
applies to low LET radiation. For Auger electrons, of high LET quality, dose rate effects 
will be less important. Other radiobiological factors are probably of lesser importance.
Redistribution: radiation typically induces a G2 block in cell cycle progression. 
Decreasing dose-rate could lead to a release of this block with progression of cells into 
more sensitive phases of the cycle. This 'inverse dose-rate effect', if it exists, may to some 
extent compensate for the decreasing radiobiological effectiveness of the diminishing dose- 
rate.
Reoxygenation\ it is difficult to predict whether hypoxia and reoxygenation will be 
important in targeted radiotherapy or not. Most of the radiation dose delivered by 
targeted radiotherapy will usually be given within a week, due to biological clearance of 
the agent and radioactive decay. This short time may not be sufficient for complete 
reoxygenation. However, the low dose-rate could result in a low oxygen enhancement 
ratio (OER), thereby reducing the importance of hypoxia (Langmuir and Medonca, 1992).
Repopulation\ In the first week of treatment by targeted radiotherapy more than 90% of 
total dose will have been received by the tumour. Therefore, repopulation is unlikely to
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be an important factor in tumour or normal tissue. When the dose-rate drops below 2-3 
Gy/h (Fowler, 1990), a certain amount of ’dose-wastage' will occur. Therapy using 
radionuclides with short half lives is therefore preferable to those with long half lives 
(O'Donoghue and Wheldon, 1996). Repopulation may play a more important role if 
targeted radiotherapy comes to be used in fractionated mode.
An additional important consideration is heterogeneity of distribution of targeting agents 
in tumours. Most analyses have assumed for simplicity, that the targeted agents were 
distributed uniformly throughout the tumour. In fact, for larger tumours, this is most 
unlikely to happen. Reasons for heterogeneity of radionuclide deposition include limited 
penetration of the agent into solid tumours as well as heterogeneous expression of the 
molecular targets themselves throughout the cells. Heterogeneity of radionuclide 
deposition has been shown by several experimental and clinical studies (Moyes et al., 
1989; Olea et al., 1992). Whether non-uniform deposition of targeted agents translates 
into heterogeneity of absorbed dose depends on the spatial distribution of the radionuclide 
in relation to the particle range. Small changes in deposition over dimensions less than 
the particle range will tend to be smoothed out by crossfire from radionuclides targeted to 
nearby cells. However, changes which are greater than the mean path length of the 
emitted particles will increase survival of tumour cells in the regions receiving less dose 
deposition. Heterogeneity will be most serious for short-range Auger and a-emitters and 
least serious for long P-emitters.
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3.3 Specific targeting vehicles
3.3.1 Antibody targeting
Monoclonal antibodies (MAbs) have been used since Kohler and Milstein's (1975) seminal 
observation that monoclonal antibodies with precise target specificity could be produced 
by fusing B lymphocytes from an immunized host to an immortalized myeloma-cell line. 
MAbs can achieve antitumour effect by several mechanisms including complement or 
antibody-dependent cytotoxicity, binding to growth factors or growth factor receptors, 
signalling of apoptosis through cell-surface molecules, and as immunoconjugates passively 
delivering radioisotopes, toxins or chemotherapeutic agents to the tumour site (Goldenberg, 
1993). Problems which are recognised include the failure to find epitopes (specific 
molecular groups on the cell surface) unique to tumour cells, heterogeneity of expression 
of epitopes, limited penetration of antibodies into solid tumours and, more generally, low 
levels of absolute antibody uptake. Approaches have been developed to improve the 
localization of radiolabelled MAbs in experimental tumours. These approaches involve 
three general strategies: a) modifying antibodies or radiolabelling techniques; b) increasing 
the clearance of radiolabelled MAbs; and c) modifying tumour delivery, tumour antigen 
expression or increasing tumour vascular permeability or blood flow (Buchsbaum, 1995).
To enhance the cytotoxicity of monoclonal antibodies against human tumours, a variety 
of cytotoxic agents have been conjugated to the antibody. The antibody serves as a 
targeting mechanism and agents such as radioisotopes, plant or bacterial toxins and drugs 
have been identified as potential therapeutic modalities in these immunoconjugates.
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3.3.1.1 Radioimmunoconiugates
Radioisotope selection is critical. Isotopes with a-decay have very short ranges of 
penetrance and require antibodies that bind to surface antigens in order to bring the isotope 
into close approximation with the cell nucleus, p-decay is associated with long path 
lengths and relatively confined radiation exposure to the sites of isotope deposition, y- 
decay produces high-energy photons which attenuate exponentially. Approximately 50% 
of the y-decay photons are absorbed by normal human tissues distant from the binding 
sites and 50% of these photons escape to the environment surrounding the patient. The 
toxicities of the various immunoconjugates must be compared with the benefits of the 
possible elimination of antigen-negative neoplastic cells in tumours.
3.3.1.2 Use of MAbs in solid tumours
MAb therapy for solid tumours has progressed rather slowly owing to a number of factors:
a) Many of these tumours are radioresistant.
b) Patients with solid tumours frequently generate human antimouse antibodies (HAMA) 
after a single exposure, which could abrogate the effect of repeated MAbs infusions 
(Jeffers et al., 1986).
c) Tumour penetrance by the immunoconjugate is less compared with lymphoma and 
leukaemia owing to differences in the vascular availability in solid tumours. 
Radioimmunotherapy has been evaluated in malignant gliomas. Some human gliomas 
amplify and rearrange the EGFR gene, resulting in generation of truncated EGFR proteins. 
Antibodies generated against these truncated proteins could be ideal candidates for 
antibody guided imaging and therapy of gliomas (Humphrey et al., 1990). Systemic and 
intracarotid administration were evaluated in ten patients with grade III or IV glioma
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(Kalofonos et al., 1989) using an antibody to EGFR labelled with 40-140 mCi of 131I. Six 
patients showed clinical improvement, with one patient remaining in remission for 3 years. 
Since gliomas remain confined to the brain, intratumoural administration has been 
considered as an alternative approach. Autoradiographic studies have shown that the 
antibody is able to diffuse from the site of injection to more remote tumour islands 
(Rowlinson-Busza et al., 1991a). Papanastassiou et al. (1993) treated patients with 
malignant gliomas by placing a ,31I-labelled MAb into the resection cavity. The systemic 
uptake was 0.13% to 14.8% of injected dose. The cause of these results may in fact lie 
not so much in the nature of the applied antibody but in the nature of the addressed target 
(Kuzel and Rosen, 1994). A critical issue for the MAbs therapy is the accessibility of 
tumour cells in solid tumours. An increasing amount of experimental data demonstrates 
that macromolecules including MAbs do not penetrate well into solid tumour tissues. 
Barriers to penetration are surrounding basement membranes and poor vascularization of 
tumours (Jain, 1991). Raben et al. (1996) have sought to address the poor intratumoural 
antigen expression by enhancement of radiolabel binding and tumour localization. They 
focused on gene transfer methods and showed that human glioma cells that do not express 
carcinoembryonic antigen (CEA) can be transduced in vitro with recombinant replication- 
defective adenovirus encoding human CEA, which renders them susceptible to binding by 
radiolabelled anti-CEA antibodies. An advantage of radiolabelled MAbs is that they can 
be active on the cells in proximity of the antigen-positive target cell irrespective of their 
antigen status. In preclinical comparative studies, the ,25I-labelled EGFR MAbs have 
shown more significant anti-glioma effect than ,3,I-labelled EGFR MAbs (Bender et al., 
1992). Brady et al. (1990) evaluated an 125I-labelled EGFR MAbs delivered intraarterially 
in 15 patients with recurrent, malignant astrocytomas. One patient showed a surgically 
documented complete response, and two patients achieved a partial response. 
Comparative study of the intra-carotid versus intravenous administration of radiolabelled
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MAbs in glioma patients did not show a significant advantage for either delivery modality 
in terms of immunoglobulin uptake in the tumour (Zalutsky et al., 1990). More promising 
results were obtained by Riva et al. (1994) who used direct intratumoural injection o f 1311- 
anti-tenascin MAbs in a series of 24 patients suffering from recurrent malignant gliomas. 
Tenascin is an antigen specifically expressed in the glioma stroma but not in normal brain 
tissue. A clear therapeutic effect was obtained in 6/17 patients (35%) and the median 
survival (16 months) was longer than that generally expected with other treatment 
modalities. The radiation doses delivered to the tumours were higher than those obtained 
by traditional external radiation therapy. In conclusion, clinical trials to date using MAbs 
for treatment of malignant gliomas have had only limited success. However, controlled 
studies are needed to evaluate the true value of these therapeutic strategies alone or in 
combination with other conventional treatment modalities.
3.3.2 Meta-iodobenzvlguanidine fMIBG)
A promising targeting agent is the radiopharmaceutical meta-iodobenzylguanidine (MIBG) 
which is preferentially taken up by catecholamine-synthesising cells of the sympathetic 
nervous system. Malignant tumours of sympathetic nervous tissues, particularly 
neuroblastoma and phaeochromocytoma, often retain the property of high MIBG uptake, 
allowing this agent to be used as a means of delivery of radio-iodine, for both diagnostic 
and therapeutic purposes (Voute et al., 1991; Lewis et al., 1991).
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3.3.3 Novel targeting vehicles
Many other potential targeting agents are now being studied. These include a variety of 
growth factors that might be used against tumours whose cells have been found to over­
express the receptor for the appropriate growth factor (Capala and Carlsson, 1991; Mairs 
et al., 1991). It is now well-established that an important group of tumours, including 
gliomas and squamous carcinomas, characteristically over-express the cellular receptor for 
epidermal growth factor (EGF) (Bigner et al., 1988; Ozanne et al., 1986). Theoretically, 
administration of radiolabelled EGF should lead to at least partially selective radionuclide 
delivery to these tumours. Experimental studies have shown that it is possible to achieve 
preferential cell kill in vitro of cells over-expressing the EGF receptors by means of 131I 
labelled EGF (Capala and Carlsson, 1991). Some of the potential problems are also 
addressed by this work which shows the rapid turnover of EGF internalized by cells, and 
possible ways to avoid this problem such as conjugation of EGF to more stable molecules 
to slow its intracellular breakdown (Andersson et al., 1992). However, the most important 
progress in the molecular biology of tumours has been the discovery of oncogenes, 
abnormal tumour suppressor genes and incidental genetic aberrations in particular tumour 
types. The challenge for targeted therapy is to make use of this knowledge to effect 
tumour cell kill or gene inactivation by means of highly selective DNA targeting of 
radionuclides with subnuclear ranges of emission for example Auger emitters.
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3.3.4 Iododeoxvuridine (IUdR)
A novel treatment approach for glioma involves DNA targeted Auger electron emitters, 
bound to iododeoxyuridine. Iododeoxyuridine (IUdR), in which the 5-methyl group is 
replaced by an iodine is an analog of thymidine (TdR) (Figure 3.1). Since a methyl group 
and an iodine atom have similar van der Waals radii, the substitution produces a compound 
that behaves like the natural pyrimidine nucleoside (Eidinoff et al., 1959; Morris and 
Cramer, 1966). IUdR is a suitable competitor of TdR for incorporation into the DNA of 
replicating cells (Halperin et al., 1988). The nucleoside salvage enzyme, thymidine kinase 
(TK), phosphorylates both TdR and IUdR (Bresnick and Thompson, 1965), to TdR 
monophosphate (dTMP) and IUdR monophosphate (IdUMP) respectively. dTMP is then 
phosphorylated to thymidine diphosphate (dTDP), by means of the thymidylate kinase 
(TMPK) catalyzed reaction, and in turn to thymidine triphosphate (dTTP) which is 
incorporated into DNA. On the other hand, IdUMP may be phosphorylated by the same 
enzyme-catalyzed pathway or dehalogenated by thymidylate synthetase (TS) to dUMP and 
then converted to dTMP (by the de novo TS pathway) and subsequently phosphorylated 
to dTDP (Garret et al., 1979) (Figure 3.2).
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Figure 3.1 The structures of thymidine and 125I-iododeoxyuridine
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Pioneering radiobiological experiments using the 125I-labelled thymidine precursor, 
[125I]IUdR, were performed in the 1970's by several investigators (Hofer and Hugues, 1971; 
Burki et al., 1973). Radiolabelled IUdR is an appropriate targeting vehicle for the 
delivery of radiation to proliferating tumour target tissue. In vitro, uptake of IUdR is 
progressive with time over several cell cycles and linear with extracellular concentration 
(Baranowska-Kortylewicz et al., 1988). It is well known that IUdR labelled with the 
Auger-emitting radionuclides 123I, 125I and 77Br is highly toxic to mammalian cells (Kassis 
et al., 1989). Because IUdR is a cell cycle-dependent agent, only cells which are in, or 
enter, S phase during the period of exposure to the drug can be effectively targeted. The 
rate of incorporation into DNA of radiopharmacutical depends on the rate of proliferation.
Four conditions must be met for IUdR, conjugated to short range emitters (alpha and 
Auger) to be used for therapy:
(a) the agent must be capable of penetrating the tumour.
(b) the IUdR must be taken up preferentially in the DNA of tumour cells.
(c) the agent should not reach proliferating normal tissue (eg. gastrointestinal tract, bone 
marrow).
(d) if the agent diffuses out of the target area, it must be converted quickly into an 
inactive/nontoxic form and be excreted rapidly from the body (Kassis et al., 1990). IUdR 
may be an agent that meets these requirements for targeting glioma.
The use of IUdR in vivo is associated with several problems. Firstly, deiodination: IUdR
is extremely stable in vitro (Kassis and Adelstein, 1996) but quite unstable in vivo. The
half life of IUdR in the circulation in humans is less than 5 min (Rey and Kinsella, 1991) 
and 7 min in mice (Prusoff, 1963). Since IUdR belongs to the class of drugs undergoing 
rapid first-pass hepatic degradation (Clifton et al., 1963), most of the tracer passing
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through the liver is rapidly deiodinated and radioactivity is released into the circulation in 
the form of free iodide which is excreted in the urine. Secondly, IUdR uptake by actively 
proliferating normal cells may cause normal tissue toxicity. These problems might be 
overcome by loco-regional intracavity administration which enhances availability of the 
drug to tumour cells, while taking advantage of dilution and rapid metabolic breakdown 
to reduce uptake in distant normal cells. A third problem arises from S phase specific 
labelling. Malignant cells which are not synthesising DNA during the time of exposure 
to IUdR, labelled with 125I or 123I, will be spared. Enhanced tumour cell uptake may be 
achieved by continuous or intermittent infusion.
Clinical evaluation of radiolabelled IUdR for the treatment of malignancies other than brain 
tumour has demonstrated therapeutic benefit. Mariani et al. (1993) found that injection 
of [125I]IUdR into colorectal tumours resulted in high values of mean uptake in the tumour 
and high tumour to non-tumour ratios. Microautoradiography confirmed that the fraction 
of cells with intranuclear uptake was also high close to the injection site. With respect 
to macroscopic and microscopic scales, uptake was very heterogeneous. Therefore they 
concluded that loco-regional methods of delivery would be required for therapeutic effect. 
In a clinical study (Kassis et al., 1996), single intracerebral injections of [123I]IUdR were 
given to patients suspected of having primary gliomas in order to determine the 
biodistribution of radiopharmaceutical and to calculate dose estimates to the tumour and 
normal tissue. They demonstrated by scintigraphic imaging that the distribution of 
radiolabelled IUdR was mainly limited to the tumour, stomach and bladder. The optimal 
use of IUdR in treatment of glioma has yet to be defined.
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3.4 Applications of the spheroid model in targeted radiotherapy research
Spheroids were first used for targeted radiotherapy studies in the 1980s as in vitro 
micrometastases models (Sutherland et al., 1987; Walker et al., 1988; Kwock et al., 1989). 
Since then a large number of experimental studies have been reported, employing the three 
dimensional structure of spheroids to investigate diffusion gradients of alternative targeting 
agents, efficacies of alternative modalities and modulating agents, to evaluate 
microdosimetry and provide experimental model systems for testing hypotheses. Some 
examples of important applications are shown in Table 3.3.
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Application Example
Factors governing antibody binding Carlsson et al.,1989; Langmuir et 
al.,1991.
Relative diffusion of antibodies and 
small molecules
Mairs et al.,1991; Petterson et al.,1992; 
Lindstorm and Carlsson, 1993.
Comparison of cell killing by X-rays, 
chemotherapy and targeted 131I
Rotmensch et al.,1994.
Comparative radioimmunotherapy using 
alternative antibodies
Langmuir et al., 1992a.
Comparative radioimmunotherapy using 
alternative isotopes
Langmuir et al., 1992b.
Microdosimetry of radionuclide therapy Bardies et al., 1992; Langmuir et 
al., 1992b.
Experimental test of microdosimetric 
hypotheses
Gaze et al., 1992.
Evaluation of radiosensitisers in 
radioimmunotherapy
Langmuir and Medonca, 1992.
Table 3.3 Applications of spheroids in targeted radiotherapy research
78
PROJECT AIMS
The goals of this study were as follows:
(a) To establish an in vitro model for IUdR mediated therapy, based on human glioma cell 
lines grown as monolayers and as multicellular tumour spheroids.
(b) To determine the uptake of IUdR in cultured cells and spheroids using flow cytometric 
DNA analysis.
(c) To determine the effect of proliferative heterogeneity and incubation time on the uptake 
of IUdR in different sizes of spheroids using flow cytometry.
(d) To examine the influence of proliferative heterogeneity and incubation time on cellular 
incorporation of [125I]IUdR, using localization of the cycle-specific nuclear antigen Ki67 
and autoradiography.
(e) To study the effect of external beam irradiation by clonogenic assay in both monolayer 
cells and spheroids and by growth delay in spheroids.
(f) To compare the therapeutic potential of IUdR labelled with different radioisotopes (123I, 
125I and 131I) using glioma cells cultured as monolayers in exponential or plateau phase of 
growth, and spheroids.
The results of these studies will form a basis for the evaluation of this therapeutic 
approach, which will be extended to animal models and ultimately human clinical studies.
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4.1 Cell culture conditions
All tissue culture was carried out in a class 2 microbiological safety hood, with vertical 
laminar air flow. Non-disposable equipment was sterilised by dry heat at 160°C for 1 
hour. Heat stable solutions were sterilised by autoclaving at 120°C for 40 minutes.
Cells were maintained subconfluent in appropriate tissue culture medium by incubation at 
37°C, in an atmosphere of 5% C 02, 20% 0 2
Human glioma lines, continuous and primary, were maintained in Eagle’s minimum 
essential medium (MEM) with 10% (v/v) fetal bovine serum, penicillin/streptomycin (100 
I.U/ml), fungizone (2pg/ml) and glutamine (200 mM). All the reagents were purchased 
from GibcoBRL (Paisley, Scotland).
Routine cell counting was performed on a Coulter counter, with settings calibrated 
separately for each cell line.
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4.1.1 Cell storage and handling of stock
All continuous cell lines were stored in liquid nitrogen, suspended in complete medium, 
with 10% (v/v) dimethyl sulphoxide (DSMO). Cells were frozen at lx 106 per ml. To 
avoid genetic drift, new cultures were initiated from frozen stocks every 6 weeks.
Stocks of each cell line were grown at the start of this project and frozen to provide 
material of similar passage level through the research.
4.1.2 Mycoplasma testing
All lines were screened for mycoplasma contamination monthly, and prior to freezing. 
Cells were fixed at 50% confluence in Petri dishes, with 25% (v/v) acetic acid in methanol, 
and incubated with the fluorescent DNA stain Hoechest 33258 at 0.05mg per ml, for 15 
minutes at room temperature. Cells were then screened by fluorescence microscopy for 
the extra-nuclear DNA pattern indicative of mycoplasma infection.
4.2 Cell line characterisation
4.2.1 Continuous lines
The following human glioma cell lines were established in this laboratory by previous 
workers: G-CCM, G-UVW, G-U251 and IP-SB18. The clinical origins of these were 
anaplastic astrocytoma, grade III and IV glioma.
At the time of undertaking the present studies all four lines had undergone more than 100 
passages.
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4.3 Plateau phase culture
105/ml cells were seeded into 24-well plates (Coming, UK), (1 ml/well) each well 
containing a 13-mm-diameter coverslip. After incubation in a humidified C 02 incubator 
for 1 to 3 days, the coverslips were transferred to 9-cm Petri dishes containing 20 ml 
medium and returned to the C 02 incubator. Medium was changed every two days after 
the cells become confluent on the coverslips. After 12 days, cell growth ceased and two 
sequential counts showed no significant increase.
4.4 Spheroid culture
One million cells were harvested from exponential monolayer cultures, seeded into 
biological Petri dishes (Bibby Sterilin Ltd., Ston, Staffs, U.K) containing 15 ml of medium 
and kept in a 5% C 02 incubator for 48 hours. Cells were then transferred to spinner 
flasks (250ml) (Techne, Cambridge, UK) containing 100 ml medium in 5% C 02 at 37°C 
and cultured until spheroids of the required size were obtained. Each of the cell lines 
when cultured as described above, grew as spheroids, but for the widest range of size of 
spheroids (100pm to 1000pm) UVW was used.
4.5 Analysis of DNA using IUdR
Flow cytometry was performed on monolayer cells in exponential and plateau growth 
phases and also on single cells derived from multicellular spheroids. Spheroids were 
treated with 0.5 ml of phosphate buffered saline (PBS) containing 0.25% (v/v) trypsin and 
ImM EDTA for 10 min at 37°C. After the addition of 0.5 ml of medium to neutralise 
the trypsin, the spheroids were mechanically disaggregated and finally passed through a
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25 gauge hypodermic needle. Microscopic examination confirmed that the cell 
preparations were free from clumps. The proportion of labelled cells was determined 
according to the following method. The cells were harvested and centrifuged at 2000g 
for 5 min. After removal of the supernatant, the cells were dehydrated and fixed in 70% 
(v/v) ice cold ethanol. DNA was denatured by the addition of 1ml of 2M HC1 followed 
by centrifugation at 2000g for 5 min. The preparation was then neutralized by the 
addition of 1ml of Borax buffer pH 8.5. After 2.5 min the cells were centrifuged and 
washed with 1ml of PBS and 1ml of PBT (PBS + 0.5% (w/v) bovine serum albumin + 
0.05% (v/v) Tween 20) for 5 min. lOOpl of a 1/30 dilution (see section 4.10) of anti- 
BudR antibody (Dako, Ltd, UK) in PBT was added to the cells, which were incubated for 
1 hour at room temperature before washing three times in PBS. The supernatant was 
removed and lOOpl of a 1/40 dilution (see section 4.10) of anti-mouse FITC-conjugated 
antibody (Dako, Ltd, UK) in PBT was added to the cells prior to incubation for 30 min 
at room temperature. After washing three times in PBS, 1ml of propidium iodide from 
a working solution (10ml PBS, 300pl Propidium iodide (PI), lmg RNase, 25pl Triton X- 
100) was added to the cells which were left for 30min at room temperature. After 
centrifugation and removal of the supernatant, the cells were resuspended in 1ml of PBS. 
Flow cytometry analysis was performed using an Epics Coulter (Florida, USA), which has 
a 15 mW argon laser emitting at 488 nm. 104 cells were analyzed using a peak versus 
area fluorescence histogram to gate out debris and cell clumps. Cell cycle distribution 
was analyzed off line using Multicycle 2.5 software (Phoenix Flowsystems, San Diego, 
USA). This work was carried out in collaboration with Dr Peter Stanton (Department of 
Surgery, Glasgow Royal Infirmary).
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4.6 Clonogenic cell survival assay after external beam irradiation
4.6.1 Determination of feeder cell requirements and linearity of plating efficiency
Pilot experiments were performed on an experimental, continuous cell line (UVW) to 
establish the range of linearity of plating efficiency, ascertain feeder layer requirements, 
and determine the optimal incubation period to obtain colonies of greater than 50 cells.
4.6.2 Cell monolayers
The colony forming ability of tumour cells irradiated in vitro was examined according to 
the following protocol. Exponential cultures of adherent monolayer tumour cells were 
trypsinised, harvested in complete culture medium and mechanically disaggregated by 
pipetting followed by passage through a 25 gauge hypodermic needle. The quality of the 
single cell suspension was assessed by microscopy, and cell numbers counted using a 
haemocytometer. Cells were subcultured into 25cm2 culture flasks at varying cell 
densities. A low density feeder layer comprising 104 heavily irradiated homologous cells 
(50Gy single dose irradiation) was added to each flask.
Flasks containing test and feeder layers were equilibrated with 5% C 02 and returned to the 
hot room where they were maintained at 37°C for a period of 4 hours prior to the 
treatment, to minimise potential interactions of trypsin and radiation lesions.
Megavoltage irradiation was carried out using a Mobaltron cobalt-60 (Thompson, 
Versailles, France) therapy source, at room temperature. Doses of 1-1 OGy were used, 
at a dose rate of 1.3-1.15Gy per minute, using full dose build up, and back scatter.
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The cultures were returned to a 37°C hot room within minutes of irradiation, then left 
undisturbed for a period of 9 to 11 days. The cultures were then washed and stained with 
10% (v/v) Carbol Fuchsin (Ziehl-Neelsen, London) and air dried before counting. The 
ability of single cells to form colonies greater than fifty cells was considered to indicate 
clonogenic survival. An automatic colony counter (Artec system Corporation 
Farminglade, USA) was used. This was calibrated against a representative plate counted 
by eye.
The plating efficiency (PE) was calculated as:
Number of colonies obtained 
PE =__ _______________________
Number of cells plated
The surviving fraction (SF) at each dose was then calculated as:
Plating efficiency of treated cells 
SF = ____________________________
Plating efficiency of control cells
The surviving fraction of cells at each dose point was plotted on a logarithmic scale, 
against dose in Gray (Gy) on a linear scale.
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4.6.3 Spheroids
Spheroids of 100-180 pm diameter were placed in Petri dishes coated with 1% (w/v) agar. 
This treatment prevented the attachment of spheroids to the bottom of the Petri dishes. 
The spheroids were then irradiated using a Cobalt-60 therapy source. Doses of 2-10 Gy 
were delivered using customised wooden and plastic blocks to provide build-up and back 
scatter radiation. They were then treated with 0.5ml of PBS containing 0.25% (v/v) 
trypsin and ImM EDTA for 10 minutes at 37°C. After the addition of 0.5 ml of medium 
to neutralise the trypsin, the spheroids were mechanically disaggregated. Microscopic 
examination confirmed that the cell preparations were free of clumps. The same protocol 
for seeding, staining and calculation of surviving fraction were used as described above.
4.7 Synthesis of precursor of radiolabelled IUdR
The preparation of radioiodinated (no-carrier-added) IUdR required the production of a 
trialklytin derivative, 5-(tributylstannyl)-2'-deoxyuridine, as substrate for the radiosynthesis. 
This precursor can be readily synthesised from IUdR by a palladium catalysed substitution 
of the iodine for a tributyltin moiety (Baranowska-Kortylewicz et al., 1994).
4.7.1 Preparation of S-ftributvlstannvP^'-deoxvuridine
Tetrakis (triphenylphosphine) palladium (5 mg, 0.004 mmol) was added to 5-iodo-2- 
deoxyuridine (0.1 g, 0.28 mmol) dissolved in 4.5 ml anhydrous dioxane. Hexabutylditin 
(0.35 g, 0.61 mmol) was introduced and the reaction mixture heated to 60°C under a 
nitrogen atmosphere for 18 hours. The solution was evaporated to dryness on a rotary 
evaporator and the dark coloured residue purified by column chromatography on silica gel
eluting with a 92:8 (v/v) mixture of CHC13 / CH3OH. Fractions containing the product 
were evaporated to dryness. 5-(tributylstannyl)-2'-deoxyuridine was obtained in a 48% 
yield (0.069 g) as a clear pale yellow oil. 1H nmr (CDC13) 8.88 (s, 1H, NH); 7.23 (d, 1H, 
CH6); 6.10 (t, 1H, CHIO); 4.58 (m, 1H, CH30); 4.02 (m, 1H, CH40); 3.82 (s 2H, 
CH50); 3.21 (s, 1H, 0H 30); 2.99 (s, 1H, 0H 50); 2.39 (m, 2H, CH20); 1.64 - 0.83 (m, 
27H, 3nBu).
4.7.2 High performance Liquid Chromatography (HPLC)
All HPLC studies employed the following solvent system: solvent A: methanol, solvent 
B: water. All solvents were passed through 0.45pm Milipore filters before use and 
maintained under a helium atmosphere during use. Confirmation of the identity of the 
radiopeak from IUdR was obtained by coelution of an authentic sample of IUdR whose 
retention time on the HPLC column was determined by UV spectroscopy (280nm). Prior 
to further use, radioiodinated IUdR was purified to remove unreacted 5-(tributylstannyl)-2'- 
deoxyuridine. The effect of 5-(tributylstannyl)-2'-deoxyuridine on the uptake of IUdR into 
cells is unknown.
4.7.3 HPLC analytical method
Analytical HPLC was carried out using an LKB 2000 series controller with 2 pumps, and 
high pressure mixer detection was achieved with an LKB UV spectrophotometer at 280 
nm. Radioflow detection was carried out using a Packard Radiomatic 500TR flow 
monitor. A 5pm Kromasil RPC 18 column (4.6 X 150 mm) with 10 mm guard cartridge 
was used with isocratic elution of 15% solvent A and 85% solvent B at a flow rate of 
lml/min. Data was analyzed using Packard FLO-ONE software.
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4.7.4 HPLC Preparative method
Purification of products was carried out on a system comprising a Waters 600 series pump 
and controller and a Wisp715 autosampler. Detection was achieved with a Waters 490 
UV spectrophotometer at 280 nm. Radiodetection was carried out using a modified Nal 
crystal and a J and P Engineering MS310 ratemeter. Purification was carried out on a 
5pm Kromasil RPC 18 column (10 X 250 mm) with 10 mm guard cartridge. A gradient 
elution profile was used as defined by the following time points:- 0 min, 15% A / 85%B; 
20 min, 15% A / 85%B; 25 min, 85% A / 15%B; 40 min, 85% A / 15%B. All gradients 
were linear. The flow rate was 3 ml/min. Data was analyzed using Waters Baseline 
software.
4.7.5 Radiochemistrv
Electrophilic iododemetallation provides a well validated method for the introduction of 
iodine into complex organic molecules at high specific activities. In order to maximise 
radiochemical yield, the oxidant and the pH of the reaction must be determined with care. 
Products formed in these reactions must be separated from the metallo precursor which is 
normally present in large excess to drive the reaction to completion. The radioiodination 
of 5-(tributylstannyl)-2'-deoxyuridine was achieved by an electrophilic iododestannylation 
reaction using peracetic acid as an oxidant and semipreparitive HPLC allowed us to readily 
separate the radiolabelled compound from the tin precursor. Unlike other oxidising agents 
used in the preparation of radioiodinated species by electrophilic iododemetallation, 
peracetic acid does not generate chlorinated side products. Peracetic acid compared 
favourably with a range of oxidants. It delivered products of consistent purity with high 
radiochemical yield.
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4.7.6 Radioiodination method
Aliquots of a solution containing 50 pg of 5-(tributylstannyl)-2,-deoxyuridine in chloroform 
were added to 300 pi V-vials (Aldrich, Dorset) and evaporated to dryness under a stream 
of nitrogen. Stored under nitrogen at -20°C, the 5-(tributylstannyl)-2'-deoxyuridine was 
stable for several months. Peracetic acid was prepared from 2ml of 35% (v/v) hydrogen 
peroxide, 1ml of glacial acetic acid and 30 pi of 98% (v/v) sulphuric acid. This mixture 
was allowed to equilibrate for 2 hours before use. To a 300 pi V-vial containing 50 pg 
of S-^ributylstannyl^'-deoxyuridine, 155 to 178 pi of acetic acid, 7.4 MBq of Na125I, 230 
MBq of Na123I or 74 MBq of Na131I (Amersham, International, UK) and 20 pi of peracetic 
acid was added. This reaction mixture was incubated at room temperature for 5 minutes 
before injecting the total volume on to a semipreparative HPLC column. The 6 ml 
fraction containing the radiolabelled IUdR was collected and evaporated to dryness in 
vacuo. The radiochemical yield of labelled IUdR in the reaction was consistently more 
than 95% which after HPLC purification gave isolated yeilds of IUdR between 60-70%. 
The IUdR was reconstituted in normal saline and sterilised by 0.22 pm filtration. 
Radiolabelled IUdR was stored at 4°C and aliquots of the reconstituted material were 
anlayesd prior to use by analytical HPLC as described previously. Synthesis of the 
precursor and labelling was carried out by Dr Jonathan Owens, Department of Clinical 
Physics and Bio-engineering, Radionuclide Dispensary, Western Infirmary.
4.7.7 HPLC analysis for deiodination of IUdR
Evaluation of deiodination kinetics was attempted using HPLC analysis. However, the 
HPLC results proved too unstable for reliance to be placed as the data, which are therefore 
not included here.
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4.8 Clonogenic assay following targeted radiotherapy
The effect of radioiodinated IUdR on clonogenicity of UVW cells was determined for 
cultures treated in exponential growth phase, in plateau growth phase and growing as 
multicellular spheroids.
4.8.1 Monolayers
Aliquots consisting of 104 exponentially growing monolayer cells were seeded into 24 
multiwell plates (Coming, New York) containing 1ml of complete MEM and incubated at 
37°C with 5% C 0 2 for 2 days. The medium was then removed and replaced with 1ml 
of medium containing a range of concentrations of [123I]IUdR, [131I]IUdR, [125I]IUdR, Na125I 
or Na131I. Controls contained equimolar non-radiolabelled IUdR or medium in place of 
radioiodinated reagents. Cell cultures in plateau growth phase were established as 
described in section 4.3 and treated similarly. The cultures were incubated at 37°C with 
5% C 02 for 44 hours (one doubling time for exponentially-growing cells. The radioactive 
medium was removed, and the cells were washed with PBS until no further soluble 
radioactivity could be eluted. They were then trypsinised, serially diluted and seeded into 
25 cm2 tissue culture flasks in triplicate. The number of cells seeded was chosen to yield 
30 to 260 colonies after 10 days. A low-density feeder layer, containing 104 heavily 
irradiated cells, was added to each flask. This procedure was shown in preliminary 
experiments to enhance plating efficiency.
92
4.8.2 Spheroids
Spheroids of 100 to 200pm diameter were transferred from bacteriological Petri dishes into 
1% (w/v) agar base-coated 6-well plates (35mm diameter) containing 4 ml medium. Each 
well contained several spheroids. These were incubated with varying concentrations of 
[123I]IUdR, [125I]IUdR or [131I]IUdR at 37°C in 5% C 02 for 52 hours (one volume doubling 
time). The spheroids were washed several times in culture medium until no further 
soluble radioactivity could be eluted. They were then treated with 0.5 ml of PBS 
containing 0.25% (v/v) trypsin and ImM EDTA for 10 minutes at 37°C. After the 
addition of 0.5 ml of medium to neutralise the trypsin, the spheroids were mechanically 
disaggregated. Microscopic examination confirmed that the cell preparations were free 
of clumps. The protocol for seeding, staining and calculation of surviving fraction was 
as described in section 4.6.2.
4.9 Incorporation of IUdR into DNA
DNA was extracted from the UVW glioma cells according to the protocol described by 
Laird et al, (1991). Cells in exponential growth phase were incubated with different 
activity concentrations of [125I]IUdR from lkBq/ml to lOOkBq/ml for one doubling time 
(44 hours) at 37°C. The unbound radiolabelled IUdR was removed after several washes 
with PBS. Then cells were trypsinized and a known number of cells were placed into a 
microfuge tube containing 0.5 ml lysis buffer (100 mM Tris.HCl pH 8.5, 5mM EDTA, 
0.2% (w/v) sodium dodecyl sulphate (SDS), 200 mM NaCl). Proteinase K (Gibco, UK) 
was added at a final concentration of 100 pg/ml and incubated at 55°C overnight. 
Following complete lysis, the tubes were vortexed and were then centrifuged for 10 
minutes. The supernatants were then poured into prelabelled tubes containing 0.5 ml of
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isopropanol. The samples were mixed by hand until a DNA precipitate was visible. The 
DNA was recovered by lifting the aggregated precipitate from solution using a disposable 
yellow tip. Excess liquid was removed and the DNA was dissolved in lx  TE buffer (10 
mM Tris.HCl, 0.1 mM EDTA, pH 7.5). The tube contents were incubated at 37°C 
overnight to ensure the DNA was properly dissolved. Cellular uptake was measured as 
DNA-associated activity per cell by gamma counting (Cobra II, Canberra, Packard).
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4.10 Solutions and reagents
Antibodies: Dako, Ltd, UK
Autoradiography: Kodak, IB I Limited, England
Iododeoxyuridine: Sigma, USA
Radiochemicals: Amersham International, UK
Tissue culture plastics from Falcon, Nunc, Denmark; Coming, UK.
Media and supplements from Gibco, Paisley.
DNA Isolation Reagents:
Lysis buffer (100 mM Tris.HCl pH 8.5, 5mM EDTA, 0.2% (w/v) SDS, 200 mM NaCl) 
TE buffer (10 mM Tris.HCl, 0.1 mM EDTA , pH 7.5)
Autoradiography:
D19 developer: 2g metol, 8g hydroquinone, 90g anhydrous sodium sulphite, 45g anhydrous 
sodium carbonate, 5g potassium bromide, 1000 ml distilled water.
Kodak Fixer, prepared according to manufacturer's instructions.
Ki67 Reagents:
Blocking serum: 25% (v/v) normal human semm, 25% (v/v) normal swine serum and PBS. 
Primary antibody: 10% (v/v) normal human semm, 10% (v/v) normal swine serum, PBS, 
rabbit anti-human Ki67 (1:100) diluted from supplied stock (Dako, Ltd, Code, A 0047). 
Control antibody: 10% (v/v) normal human semm, 10% (v/v) normal swine semm, PBS, 
normal rabbit immunoglobulin diluted 1/400 from supplied stock (Dako, Ltd, Code, E 
353).
Secondary antibody: 10% (v/v) normal human semm, 10% (v/v) normal swine serum, 
biotinylated pig anti-rabbit immunoglobulin diluted 1/400 from supplied stock (Dako, Ltd,
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Code, 353).
sABC reagent (strep Avidin Biotin- peroxidase Complex): prepared 30 min prior to use by 
diluting in PBS containing 2% (v/v) normal human serum.
Diaminobenzidine (DAB): 0.05% (w/v) (diaminobenzidine tetrahydrochloride containing 
0.01% (v/v) hydrogen peroxide (H20 2) in PBS.
Flow cytometry reagents:
propidium iodide (PI) stock solution (10ml PBS, 300pl PI, lmg RNase, 25pl triton X-100) 
PBT (PBS + 0.5%bovine serum albumin + 0.05% Tween 20)
Anti-BudR antibody, diluted 1/30 from supplied stock (Dako, Ltd, Code, M 744).
Anti mouse FITC antibody, diluted 1/40 from supplied stock (Dako, Ltd, Code, F 0479).
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Biology of human glioma cell lines
97
5.1 Characterisation of human glioma continuous cell lines .......................................... 99
5.1.1 Introduction................................................................................................................99
5.2 Methods and materials ....................................................................................................100
5.2.1 Morphology ........................................................................................................... 100
5.2.2 Population doubling times in monolayer culture .............................................. 100
5.2.3 Volume doubling time in spheroid culture .......................................................101
5.2.4 Glial fibrillary acidic protein (G F A P ).................................................................102
5.2.5 Karyotype analysis of UVW cells ......................................................................102
5.2.6 Cell cycle an a ly s is ................................................................................................. 102
5.2.7 Ploidy ......................................................................................................................103
5.3 Results ................................................................................................................................104
5.3.1 Morphology ............................................................................................................104
5.3.2 Doubling time of glioma cell l in e s ......................................................................107
5.3.3 Karyotypic analysis of UVW line .......................................................................... 110
5.3.4 Cell cycle analysis....................................................................................................113
5.3.5 Ploidy ......................................................................................................................115
5.4 Discussion ...........................................................................................................................117
98
5.1 Characterisation of human glioma continuous cell lines
5.1.1 Introduction
The human glioma cell line U251 used in this study was initially described by Ponten (1975). 
SB 18 was established by Pilkington and Lantos (1982) and UVW was established in the 
Department of Medical Oncology, University of Glasgow. All were anaplastic astrocytoma, 
grade III and IV glioma.
The UVW cells line was chosen because of its ability to grow as very large and regularly 
shaped spheroids in comparison to other cell lines. Therefore, we decided to characterise the 
UVW cell line. The rationale for this was as follows.
The UVW human glioma cell line used in the present investigations, was established in this 
lab in the early 1980s as part of a study of the phenotypic differences between normal and 
malignant glia. This line was used as a tumour model as part of a research program on the 
mechanisms of human tumour chemoresistance (Merry et al., 1984). At the commencement 
of the project all glioma lines had been passaged more than 100 times and therefore a re­
assessment of their biological characteristics was considered important.
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5.2 Methods and materials
5.2.1 Morphology
The cell lines used in this study grew as adherent monolayer cultures on tissue culture grade 
plastic. Morphological examination was made in mid-log phase of growth using bright field 
microscopy.
5.2.2 Population doubling times in monolayer culture.
To determine the population growth curves for each cell line, cells from early-culture passage 
of monolayer growth were harvested and 104 cells were seeded into two individual 24 
multiwell plates, and allowed to adhere. On the second day after seeding, 0.5 ml of 0.25% 
trypsin in ImM EDTA was added to three wells and the cells were counted using a Coulter 
counter (Coulter Electronic, Luton, England) calibrated for each cell line. This procedure 
was repeated daily for 18 days. The medium was replaced every day with 1ml fresh medium 
to maintain the cells in exponential growth. The mean of three counts were used to calculate 
the doubling time. Preliminary growth curves showed that log phase growth started at day 
2 or 3 and the cells reached a plateau between days 8 and 18. Terminal density was judged 
to have been achieved when cell counts remained constant over 3 consecutive days. 
Population doubling times were calculated from the exponential portion of the growth curves 
by means of the equation:
Td = 0.693 / X
Where Td is the mean doubling time and X is mean slope of the exponential portion of the 
growth curve.
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5.2.3 Volume doubling time in spheroid culture
Spheroid growth rates were measured to provide a basis for the selection of incubation times 
for radiolabelled and non-radiolabelled IUdR. Cultures of spheroids were initiated by 
inoculating 106 cells into a bacteriological Petri dish containing 15 ml of medium. After two 
days of incubation in 95% air / 5% C 02 at 37°C, cell aggregates of approximately 100 pm 
diameter were selected and transferred to 24-well plates coated with 1% (w/v) agar, 
containing 0.5ml of medium per well. Each well contained a single aggregate which 
subsequently grew as a tumour spheroid. 0.5 ml of fresh medium was added every 7 days. 
At 2 to 4 day intervals, each spheroid was evaluated by measuring 2 perpendicular diameters, 
using an inverted, phase-contrast microscope connected to an image analyzer. The volume 
of the spheroids was calculated from the equation:
V= a x b2x 71/6
Where a and b are the longest and shortest diameters respectively. Growth kinetic data were 
fitted (using BMDP program 3R) to a Gompertzian equation, which is defined by the 
following relationship:
V(t) = V(0) exp [(A/a ) (1 -exp[ -at] )] 
where V(t) and V(0) are the volume of the spheroid at times t and 0, respectively and A and 
a  are parameters. UVW glioma spheroids initially grew exponentially but then underwent 
a progressive reduction in growth rate, and this pattern showed a good fit to a Gompertzian 
equation.
The volume doubling time of the initial exponential part of the growth curve, calculated as 
In2/A, was 52 hours.
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5.2.4 Glial fibrillary acidic protein (GFAP")
To determine expression of the astrocytic lineage marker, GFAP, 104 UVW tumour cells were 
seeded in lOOpl of medium onto polylysine-coated sterile coverslips in 24 well plates, and 
allowed to adhere. The cells were fixed with ice-cold methanol, and left for 15 minutes, at 
-20°C, prior to brief rehydration with Hanks staining medium. Rabbit anti-human GFAP 
(Dako, Ltd, UK) was added in 50 ml Hanks medium, and left for 45 minutes. Coverslips 
were then washed in Hanks medium, and a goat anti-rabbit polyclonal second antibody 
conjugated to fluorescein (Southern Biotechnology) was added. Coverslips were treated with 
Cityflor antifade, and mounted cell-down on microscope slides, sealed with nail varnish to 
prevent movement, and dried. Cells were then examined for fluorescence using a Reikert 
Polyvar microscope. The percentage of total stained cells was then estimated. The human 
lung carcinoma line, A549, was used as a negative control.
5.2.5 Karyotype analysis of UVW cells
Karyotype analysis was carried out by the Department of Medical Genetics, Royal Hospital 
for Sick Children, Yorkhill, Glasgow.
5.2.6 Cell cycle analysis
Cells were grown as monolayers in exponential or plateau phases as described in sections 4.1 
and 4.3. They were then trypsinised, rinsed well in PBS and fixed in 70% (v/v) ethanol. 
Before analysing, cells were pelleted by centrifugation, resuspended in 1.6 ml of PBS, 0.2 ml
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RNase (lmg/ml) (Sigma) and 0.2 ml propidium iodide (PI) (400pg/ml). PI is a 
stoichiometric DNA dye suitable for monitoring the percentage of cells in the G„ S, and G2/M 
phases of the cell cycle on the basis of the cellular DNA content (Pucillo et al, 1990). After 
incubation for 30 min at 37°C, cells were pelleted by centrifugation, and resuspended in PBS. 
The cells were analysed using a Coulter Epics Profile II (Epics Coulter corporation, Florida, 
USA). Each analysis was the result of 10,000 nuclear counts on each sample. S phase 
fraction was then calculated by offline analysis using Multicycle software (Phoenix 
Flowsystems, San Diego, USA).
5.2.7 Ploidy
Flow cytometric analysis of cellular DNA content was used to establish cell line ploidy. For 
this purpose UVW nuclei were gently vortexed and one drop of chicken erythrocyte nuclei 
(CEN) (Becton Dickinson, Erembodegem, Belgium) was dispensed into the tube, to which 
lml of PI stain solution was then added. CEN act as internal reference standards for the 
determination of G0/G, cell DNA content. The tube was capped, gently vortexed and 
incubated for 10 minutes at room temperature, protected from the light. Cytometry was 
performed on a Becton Dickenson Florecent Activated Cell Sorter (FACS) using control 
aliquots of the suspension of PI stained nuclei. Each analysis was the result of 10,000 
nuclear counts on each sample.
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5.3 Results
5.3.1 Morphology
The morphology of the glioma cell lines growing in monolayer culture are shown in Figures 
5.1-5.4. The morphological features, phenotypic and genotypic characteristics of the three 
continuous glioma lines are summarised in Table 5.1.
Table 5.1 Phenotypic and genotypic characteristics of human glioma cell lines.
Cell line UVW U251 SB18
Passage level >100 >100 >100
Morphology fusiform epithelioid fusiform
Doubling time (hrs) 44 32 39
Monolayer + + +
Spheroid + + +
GFAP — + +
DNA index 2.9 ND* ND*
S phase fraction 13.6 19.6 16.5
G0/Gj 70.8 74 79.3
g 2/m 15.6 6.4 4.2
*ND = Not determined
1 0 4
Figure 5.1 Phase contrast micrographs of (a) UVW monolayer and (b) UVW spheroid.
200pm spheroid.
Figure 5.2 Phase contrast micrographs of monolayer (a) U251, and (b) SB 18. 
Magnification: x 150
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5J J? Doubling time of glioma cell lines
Glioma cell lines showed a lag phase of 24-48 hours before achieving exponential growth. 
The population doubling times (TD), calculated from the slopes (X) of the exponential part of 
the growth curves, of cell lines SB 18, U251 and UVW, were 39 hrs, 32 hrs and 44 hrs 
respectively. This data is summarized in Table 5.2.
Cell lines X (day_1 ) 
(±SEM)
Td (hrs)
SB18 0.426±0.03 39
U251 0.513±0.04 32
UVW 0.376±0.07 44
Table 5.2 Growth curve parameters of glioma cell lines calculated by linear regression 
analysis using SPSS (statistical package) (SPSS Inc, USA) .
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Figure 5.4 Spheroid growth curve. The ordinate is the common logarithm of 
spheroid volume in pm3. Each point represents the mean (+SEM) of at least 
13 values, calculated from measured cross sectional area. The curve represents 
a Gompertzian equation fitted to the data by the relationship:
V(t) = V(0) exp [(A /a) (l-exp[- a  t])] 
where V(t) and V(0) are the volume of the spheroid at times t and 0, 
respectively and A and a  are parameters. The parameters of the fitted curve are 
V(0) = 6.08 log pm3, A = 0.319 d ay1, a  = 0.122 d ay 1.
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5.3.3 Karyotypic analysis of UVW line
Three cells from this line have been karyotyped from photomicrographs. Table 5.2 shows 
the three cells (A,B, and C) with the number of normal homologues of each chromosome 
followed by any structural abnormalities involving that chromosome. Any additional or 
missing material is denoted as + or and its position as to whether it is on the short arm (p) 
or long arm (q) has been noted. Due to the highly rearranged nature of these cells it was 
not possible to fully characterise all the chromosomes and those in which the centromere 
could not be identified have been classed as 'Markers'.
110
Chromosome 1 2 3 4 5 6 7 8 9 10 11
A 1 2 3 4 5 6 7 8 9p+ 10 11
1 2 3 4 5 6 7 8 9p+ 10 11
2 3 4q+ 5 6q- 7 8p+ 10 llq +
6q- 7
B 1 2 3 4 5 6 7 8 9p+ 10 11
1 2 3 4 5 6q- 7 8p+ 9p+ 10 11
2 3P" 4q+ 5 6q- 7 9p+ 10 llq +
i(7)p
C 1 2 3 4 5 6 7 8 9p+ 10 11
lq- 2 3 4q+ 5 6 7 8 9p+ 10 11
2 3 5 6q- 7 9p+ 10 llq +
6q- 7 9p+
i(7)p
Chromosome 12 13 14 15 16 17 18 19 20 21 22
A 12 13 14 15 16 17 18 19q+ 20 21 22
12 13 14 15 16 17 18 19q+ 20 21 22
12 15 17
17
19q+ 21
B 12 13 14 15 16 17 18 19q+ 20 21 22
12 13 14 15 17 18 19q+ 20 21 22
17 19q+ 20 21
C 12 13 14 15 16 17 18 19q+ 20 21 22
12 13 14 15 16 17 18 20 21 22
15 17 18 21 22
21
Chromosome X Y Markers Count
A Xp+
Xp+
Y 12 78
B Xp+
Xp+
Y 12 72
C Xp+
Xp+
Y 10 74
Table 5.3 Karyotype analysis of UVW glioma cell line.Any additional or missing material 
is denoted as + or and its position as to whether it is on the short arm (p) or long arm (q) 
has been noted. Those chromosomes in which the centromere could not be identified have 
been classed as 'Markers'.
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figure 5.5 Photograph showing the karyotype of the UVW cell line.
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j j . 4  Cell cycle analysis
The percentage o f cells in S phase, measured by flow cytometry, in exponentially growing 
cells and cells m plateau phase o f growth was 13.6% and 7.4% respectively. Histograms are
shown in Figure 5.6.
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Figure 5.6 Flow cytometry analysis of UVW cells in exponential and plateau phase culture. 
The Y axis indicates the number of cells. The number of fluorescence channels is indicated 
on the X axis.
(A) Exponential growth phase. (B) Plateau growth phase.
The percentage of cells in S phase in exponentially growing cultures was nearly twice as 
high as the percentage in plateau phase cultures.
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5.3.5 Ploidy
The DNA content of the tumour cells relative to the normal cells can be expressed in terms 
of the DNA index. This is the ratio between the DNA content of the tumour Gq/Gj cells and 
the normal G0/Gj cells. In this experiment, chicken erythrocyte nuclei (CEN) form peaks on 
the FL2-Area histogram at channels 87, 200 and 300. The human diploid peak should fall 
between channels 200-315. The UVW peak was collected at channel 707, giving a DNA 
index between 2.3 and 3.5, which represents a hypertetraploid DNA content.
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Figure 5.7 (A) Histogram of PI stained CEN demonstrating resolution and linearity. (B) 
Ploidy study of UVW cells in monolayer exponential culture. The Y axis indicates the 
number of cells against typical CEN and UVW cells peak channels on the X axis.
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5.4 Discussion
The aim of this project was to determine the effect of heterogeneous proliferative activity of 
cells on the therapeutic potential of radioiododeoxyuridine. An important part of this work 
was therefore obtaining appropriate models for the study of human gliomas in vitro. As a 
tool in the study of radiation responses of tumour cells, these cells can be cultured in the form 
o f three-dimensional multicellular spheroids. The use of spheroids as a tumour model is 
described in detail in section 2.4.
The human glioma cell lines used in this study were UVW, SB 18 and U251. They exhibited 
a heterogeneous range of phenotypic characteristics and displayed colony formation in 
monolayer culture with plating efficiencies ranging from 10-25%, using 10% (v/v) fetal calf 
serum and a low density feeder layer of homologous, heavily irradiated cells.
The three human glioma lines were compared for their suitability for the assessment of 
radiolabelled IUdR in the treatment of human glioma. The continuous line UVW was 
established in this lab before advent of this study and had been used previously by other 
groups (Freshney, 1984; MacDonald et al., 1985). All cell lines grew as spheroids but the 
UVW cell line was regarded as the most satisfactory in vitro model because of its capability 
to grow as very large and regularly shaped spheroids. The latter characteristic was essential 
for our study of the effect upon targeted radiotherapy of proliferative heterogeneity, which 
increases with spheroid size. The phenotype and genotype of the UVW glioma cell line was 
determined. This cell line lost its ability to express glial fibrillary acidic protein (GFAP) (see 
section 2.3), a cytoskeletal protein which is considered to be a marker of the astrocytic
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lineage (Bignami et al., 1972). The pattern of expression of this marker is progressively 
altered with serial passage (Frame et al., 1984) and is likely to be heavily influenced by 
culture conditions. Many researchers have reported the loss of GFAP positivity within the 
first few early passages of malignant glial culture (Kennedy et al., 1987; Westphal et al., 
1990).
The analysis of cellular DNA content provides information about the proliferative state of cell 
populations and about cell responsiveness to various stimuli. For example, tumour cell 
ploidy, and DNA index may be used as prognostic factors (Dressier et al., 1989). The UVW 
cell line was highly aneuploid and contained populations of cells which were sub-tetraploid 
by karyotype analysis. Flow cytometric analysis of UVW cells indicated a range of ploidy 
from sub-tetraploidy to hyper-tetraploidy confirmed that UVW is a highly aneuploid cell line.
Flow cytometric analysis of the UVW cell line cultured as monolayer in exponential growth 
or plateau phase showed the percentage of cells in S phase in exponentially growing culture 
to be 13.6%, while it was 7.4% in plateau phase cultures (Figure 5.6). Toward the end of 
the log phase, the culture became confluent when all the available growth surface was 
occupied and all the cells were in contact with surrounding cells. Following confluence, the 
growth rate of cultures was reduced, and in some cases, cell proliferation ceased almost 
completely after one or two doubling times. The reduction of the growth after confluence 
was not due only to contact but may also have involved reduced cell spreading (Folkman and 
Moscona, 1978), depletion of nutrients, and particularly growth factors (Holley et al., 1978), 
a reduction in cellular proliferation rate, a decrease in extracellular pH, oxygen tension and 
an increase in lactic acid and catabolite concentration (Bhuyan et al., 1977). Plateau growth
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does not imply complete cessation of cell proliferation but represents a steady state where cell 
division is balanced by cell loss. These characteristics of plateau-phase culture, closely 
resemble those found within the hypoxic microenvironment of tumours, whereas cells in 
exponential growth exist in conditions that are analogous to cells growing close to blood 
vessels. These differences between plateau-phase and exponentially growing phase cells, 
provide a foundation for the development of an approach for glioma treatment using 
radiolabelled IUdR.
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Radiosensitivity of the human glioma cell line uvw
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6.1 Aim: The aim of this study was to assess the effect of external beam irradiation on 
UVW cells in both monolayer and spheroid culture, in order to determine the radiosensitivity 
o f this cell line under different conditions of culture. In particular we wished to establish a 
dose response for uniform irradiation for comparison with the response to IUdR targeted 
radiotherapy.
6.2 Introduction
The vast majority of glioblastomas will recur in the irradiated field because this highly 
malignant glioma is radioresistant at a dose level which is at the limit of tolerate of normal 
brain tissue (Wallner et al., 1989). Several mechanisms could contribute to this clinical 
radiation resistance, such as efficient repair of radiation damage, a high intrinsic cellular 
radiation resistance and /or a rapid repopulation between fractions (Taghian et al., 1993). In 
order to establish the sensitivity of UVW cells to conventional radiotherapy by a standard 
technique, and to provide a basis for comparison of the efficacy of DNA-targeted radiotherapy, 
experiments were carried out to study the effect of single dose irradiation on UVW spheroids 
and monolayer cells. The radiation effect was evaluated by the assessment of regrowth delay 
and clonogenic assay in spheroids and by clonogenic assay in monolayer cultures.
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6.3 Methods and materials
6.3.1 Spheroid culture
Spheroids were cultured according to the method described in section 4.4.
6.3.2 Spheroid growth delay after external beam irradiation
Spheroids of 100-180 pm diameter were placed in Petri-dishes coated with 1% (w/v) agar and 
irradiated using a cobalt-60 therapy source (Thompson, Versailles, France). Doses of 2-10Gy 
were delivered using customised wooden and plastic blocks to provide build-up and back 
scatter radiation. Spheroids were then placed individually into the wells of multiwell plates 
containing 0.5 ml of medium and coated with 1% (w/v) agar. This treatment prevented the 
attachment of spheroids to the bottom of the wells. Care was taken to ensure that 
approximately the same size of spheroids were used in control and test plates.
Spheroid growth was monitored by an Image Analyzer (Analytical Measuring System, Saffron, 
Essex) three times per week and 0.5 ml of fresh medium was added every 7 days. One 24 
well plate was used for each dose point. Using a computer programme, (Dr G.M. Ford, 
Department of Clinical Physics and Bio-engineering, Glasgow) each measured area was 
converted into volume on the assumption that the spheroids were perfect spheres. Spheroid 
growth delay is presented in terms of specific growth delay, (Steel, 1984). This expresses 
growth delay in terms of the number of additional doublings which treated spheroids must 
undergo to reach the same volume as untreated controls. Spheroid growth curves were 
obtained by calculating the median volume of the spheroids in each experimental group on
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each day of measurement. The surviving fraction for each experimental group was estimated 
by extrapolation of the exponential portion of the regrowth curve to the Y axis and calculation 
of the difference between effective log volume (given by the intercept) and initial log volume 
as measured immediately before irradiation (Figure 6.1).
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Irradiated
Figure 6.1 General principle of estimation of cell surviving fraction from spheroid regrowth 
curve. Extrapolation of the regrowth curve to zero time yields an estimate (VE) of the 
'effective volume' from which the spheroid appears to have regrown i.e. it represents the 
volume of viable cells following treatment. The ratio VE to the measured volume V0 
(representing the volume of all cells initially present) provides a measure of the cellular 
surviving fraction immediately following treatment.
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6.3.3 Clonogenic cell survival assay after external beam irradiation
The radiation protocol and clonogenic cell survival assay for monolayers and spheroids were 
performed by the methods described in sections 4.6.
6.4 Results
6.4.1 Spheroid growth delay
Figure 6.2 shows spheroid growth curves for the UVW cell line as a function of dose. The 
surviving fractions, calculated as described in section 6.3.2 and radiobiological surviving curve 
parameters are given in Table 6.1, where they are compared with the surviving fractions for 
spheroids as determined by clonogenic assay.
6.4.2 Clonogenic assay
Spheroids and monolayer experiments were performed with five and ten dose points 
respectively. The results are shown in Figure 6.3. Both survival curves were well fitted by 
the linear-quadratic equation (see chapter 2 for methodology) and the parameters of the curves 
are given in Table 6.1. The survival curves of spheroids had a greater degree of curvature 
than those of monolayers, corresponding to a larger p value for the fitted curve. Also shown 
in Table 6.1 are the survival fractions for monolayers and spheroids at a dose of 2Gy.
There was good agreement between the results of the growth delay and clonogenic assay 
experiments for the survival fraction for spheroids (Table 6.1, Figure 6.4).
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Table 6.1 Radiobiological survival curve parameters for UVW spheroids and exponentially 
growing monolayers calculated by regression analysis using the SPSS statistical package.
Cell culture a  G y1 
(±SEM)
p G y 2
(±SEM)
s f 2
monolayer 0.289±0.03 0.023±0.004 0.55
Spheroids
(CA)
0.007±0.05 0.045±0.006 0.93
spheroids
(GD)
0.007±0.04 0.049±0.004 0.83
The linear-quadratic components (a  and P) show similar results for both clonogenic and 
regrowth delay techniques. SF2 values (surviving fraction at 2Gy) are compared for both 
monolayers and spheroids cultures.
CA = Clonogenic assay 
GD = Growth delay
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Figure 6.3 Surviving curves of UVW multicellular spheroids and 
monolayer cells calculated from clonogenic assay after external 
beam irradiation. The fraction of surviving cells is plotted on a 
logarithmic scale against dose on a linear scale. The filled circles 
represent monolayer cultures and triangles the spheroid cultures.
129
0.001L
0
Clonogenic assay
j — — i---------- 1-----------L
2 4 6 8 10
Dose (Gy)
0.001
Regrowth Delay
J  1----------1----------L
0 2 4 6 8 10
Dose (Gy)
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6.5 Discussion
In these experiments, we assessed the effect of external beam radiation on UVW monolayers 
and spheroids in order to establish the radiosensitivity of this cell line by a standard technique 
which allows comparison with other cell lines and to provide a basis for comparison with the 
surviving fraction obtained after radionuclide treatment, as described in later chapters.
Survival curves for spheroids were determined by two independent methods: growth delay and 
clonogenic assay. The first of these techniques is potentially subject to inaccuracy because 
it requires the subjective identification of the exponential part of the growth curves for curve 
fitting. The clonogenic assay is regarded as the most reliable method of determining cell 
survival, but is still dependent on the assumption that the number of colonies formed after 
dissociation and sampling is an accurate measure of the number of surviving cells in the 
spheroids. The fact that both techniques yielded similar results at all doses provides a high 
degree of confidence that errors were small.
Fertil and Malaise, (1981) and Deacon et al. (1985) suggested that intrinsic radiosensitivity 
of tumour cells measured by the surviving fraction at 2Gy (SF2), could play a critical role in 
tumour response to radiation treatment. However, Taghian et al. (1993) documented that the 
parameter SF2 is useful to discriminate between the sensitivity of different grades or types of 
histology in vitro but is not a predictor of the clinical outcome on an individual basis for 
malignant glioma. According to the categories of clinical radioresponsiveness illustrated by 
Deacon et al. (1984), glioma was placed in category E with an average SF2 value of 0.52 
which was consistent with the SF2 value of 0.55 for monolayer cells and 0.83-0.9 for
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spheroids constructed from UVW cells. These results were also in agreement with the results 
gained by Allalunis-Tumer et al. (1990), who reported a wide range of intrinsic radiation 
sensitivity in different glioma cell lines, the most radiosensitive having an SF2 of 0.15 and 
the most radioresistant having an SF2 of 0.93.
Spheroids are more resistant to killing by ionizing radiation than monolayers. The increase 
in radiation resistance was confined largely to the shoulder of the radiation survival curve, 
implicating differences in cellular capacity to sustain and repair damage (Hinz and Dertinger, 
1983). If at the time of irradiation the cells are out of the cell cycle and in a nonproliferative 
state, cells can be induced into proliferation at any time after the irradiation. If there is a 
time delay, repair of potentially lethal damage (PLD) is likely to occur. This process stops 
when the cells are induced into cycle, by induction of proliferation to form colonies. 
Recovery from PLD of noncycling cells in 9L rat gliosarcoma spheroids and monolayers was 
described by Rodriguez et al. (1988). They showed that spheroid cells were more resistant 
than monolayer cells and concluded that difference in time to recruit cells into the cell cycle, 
is responsible for this difference in radioresistance. The results obtained in this study are 
consistent with this interpretation.
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Flow cytometric cell cycle analysis
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Non-radioactive IUdR uptake studies
7.1.1 Aims
The aim o f this set of experiments was to determine the suitable concentration of IUdR which 
was necessary for in vitro experiments as a basis for determination of the uptake of IUdR in 
cultured cells and spheroids by DNA analysis. We further wished to investigate the effect 
of incubation time on IUdR uptake in different cell cultures.
7.2 Introduction
Knowledge of proliferation in human tumours can provide valuable information which may 
be used prognostically or diagnostically to select appropriate treatment scheduling. Cell 
kinetics studies have helped to elucidate the growth characteristics of various types of human 
brain tumours and to predict their biological malignancy (Hoshino and Wilson, 1979). 
Traditional methods to measure cell kinetics have involved the use of radioactive precursors 
of DNA, in particular tritiated thymidine, and autoradiography to visualize the incorporation 
of radionuclides into cells (Mayer and Connor, 1977; Kury and Carter 1965). However 
autoradiographic studies may require several months to complete and therefore the results are 
of limited value in supplementing treatment in individual patients. For this reason and 
because of the radiation hazard associated with 3H-thymidine, it has never become popular 
for measuring cell kinetics (Tannock, 1978).
An alternative technique uses flow cytometry to study the incorporation of bromodeoxyuridine 
(BUdR) relative to DNA content measured by propidium iodide (PI). Like thymidine and 
IUdR, BUdR is incorporated into DNA during S phase. Anti-BUdR antibody can be used
135
to measure the proportion of dividing cells. Advantages of flow cytometry over tritium 
autoradiography include speed, quantitative power, and ability to make several measurements 
simultaneously. Several studies have used flow cytometric techniques in the assessment of 
proliferative activity in brain tumours after the incorporation of IUdR or BUdR (Nishizaki et 
al., 1989; Assietti et al., 1990; Perez et al., 1995).
The flow cytometric technique has been adapted in the present study to measure the uptake 
of IUdR by UVW glioma cells under different conditions. The essence of the procedure is 
to label with IUdR by incubation in vitro. After fixation of the cells in ethanol, they are 
stained using a monoclonal antibody against IUdR that can be bound to a second antibody 
conjugated with FITC (fluorescein isothiocyanate). The cells are then counterstained with 
PI to measure the DNA content and analysed on the flow cytometer for red (DNA) and green 
(IUdR) fluorescence. The relative movement of the IUdR-labelled cells through the cell 
cycle was not measured in these experiments; the red fluorescence was used only to count the 
total number of cells and allow the calculation of the IUdR labelling index. Because of 
background fluorescence due to cellular debris, the technique should allow the estimation of 
proportions of cells in cell cycle phases with errors of approximately 10% (Dean et al., 1982; 
Haag et al., 1987).
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7.3 Materials and methods
7.3.1. Effect of IUdR concentration on incorporation in monolayer cells
The uptake of IUdR was studied to measure the suitable concentration required for flow 
cytometric analysis. 5-iodo-2’-deoxyuridine (Sigma, Poole, Dorset) was dissolved in 
medium to prepare IUdR solutions ranging in concentration from lOnM to lOOpM. The 
solutions were sterilised by filtration using 0.22pm mesh Millipore filters (Millipore, 
Molsheim, France). Monolayer cells in exponential phase were incubated with IUdR solutions 
after equilibrating with 5% C 02. The cells were incubated for one doubling time (44 hours) 
at 37°C. They were fixed and labelled with anti-BUdR antibody and PI according to the 
protocol described in section 4.5. The IUdR labelling index was calculated by expressing 
the number of nuclei incorporating IUdR as a percentage of all Pi-labelled nuclei.
7.3.2. Effect of IUdR concentration on incorporation in spheroids
The uptake of IUdR was studied using two different ranges of size of spheroid (300-400pm 
and 700-1000pm diameter). The flow cytometric procedure was as described for monolayer 
cells. Spheroids were cultured according to the protocol described in section 4.4. Spheroids 
were transferred from spinner flasks into 25cm2 flasks coated with 1% (w/v) agar. After 
equilibrating with 5% C 02, the spheroids were incubated with different concentrations of 
IUdR for one doubling time (52 hours for UVW spheroids) at 37°C. Spheroids were washed 
several times in PBS and then disaggregated by treatment with 0.5 ml of PBS containing 
0.25% trypsin and ImM EDTA for 10 minutes at 37°C. Microscopic examination confirmed 
that the cell preparation was free from clumps. Labelling and counting was the same as for
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monolayer cells.
7.3.3 The effect of incubation time on IUdR uptake in monolayer cell cultures
To find the effect of incubation time on IUdR uptake in monolayer cell cultures, cells in 
exponential and confluent cultures were incubated with lOpM of non-radiolabelled IUdR for 
one to three doubling times (44 to 132 hours). After washing several times with PBS, the 
cells were trypsinized and fixed by 70% (v/v) ice cold ethanol. The cells were labelled with 
anti-BUdR antibody according to the protocol described in section 4.5.
7.3.4 The effect of spheroid size and incubation time on IUdR uptake
Uptake of IUdR was studied using different sizes of spheroid (100-200pm and 700-1000pm 
diameter) and different incubation times to find the effect of incubation time on IUdR uptake 
in small and large spheroids by flow cytometry. Spheroids were transferred from spinner 
flasks to 25cm2 flasks coated with 1% (v/v) agar. After equilibrating with 5% C 02, the 
spheroids were incubated with lOOpM of cold IUdR for one to four volume doubling times 
(52 to 208 hours) at 37°C. The protocols for fixing and labelling were as described above.
7.3.5 Statistical analysis
The relationship between the IUdR labelling index and incubation time for each mode of cell 
culture was analysed by linear regression. The labelling indices after incubation for two or 
more doubling times were also compared on a pairwise basis with the labelling index after
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one doubling time using Dunnetfs test (Dunnett, 1955). Student's t test was used to compare 
labelling indices for different culture modes (exponentially-growing versus plateau phase 
monolayers and small versus large spheroids). In all cases a p value of less than 0.05 was 
considered significant.
7.4 Results
7.4.1 IUdR concentration for monolayer studies
Figure 7.1 shows the percentage of labelled cells over the range of IUdR concentrations from 
lOnM to lOOpM. A constant, maximum percentage of labelled cells was obtained at 
concentrations of lpM  or higher, and it was decided to use lOpM IUdR in the experiments 
which were designed to evaluate the effect of incubation time on labelling index. IUdR 
concentrations less than 0.1 pM resulted in complete absence of staining with anti-BUdR 
antibodies.
7.4.2 IUdR concentration for spheroid studies
This study was undertaken to determine the amount of uptake of cold IUdR required for flow 
cytometry experiments with UVW multicellular spheroids. The incorporation of IUdR was 
studied after incubating for one doubling time over a range of IUdR concentration between 
lOnM to lOOpM. Two sizes of spheroid (300-400pm and 700-1000pm diameter) were 
selected to examine the size-related effect of proliferative heterogeneity on IUdR uptake. 
The relationship between concentration of IUdR and incorporation is shown in Figure 7.2. 
In contrast to the results for monolayer cells, IUdR labelling did not reach a clearly defined
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maximum for either of the size ranges of spheroids. However, the apparent labelling index 
at an IUdR concentration of lOOpM was sufficiently high to be accurately determined. Also 
a concentration of lOOpM was similar to the maximum levels occurring clinically. 
Therefore, it was decided to use this concentration for the experiments on the effect of 
incubation time. There was essentially no staining with anti-BUdR antibodies in spheroids 
for IUdR concentrations less than 0.1 pM.
7.4.3 IUdR uptake in monolayer cultures
The effect of proliferative heterogeneity on IUdR uptake was studied in exponential phase 
cells (low level heterogeneity) and confluent cells (higher level of heterogeneity). Cells were 
incubated with lOpM of IUdR for one to three doubling times. Figure 7.3 shows the IUdR 
labelling index in monolayer cells in exponential and plateau phases.
The labelling index for exponentially-growing cells remained constant (r=0.00) and high 
(mean 97%) over the range of incubation times. In the case of confluent cells the labelling 
index increased with increasing incubation time (r=0.94, pO.OOl), ranging from a mean of 
61.5% (SE±1.7%) after one doubling time to 84.8% (SE±1.9%) after three doubling times. 
The linear regression equation relating labelling index (LI) and incubation time (T) in units 
of doubling times was LI = 50.1 + 11.5 T. Pairwise comparison of the groups showed that 
the labelling index after two and three doubling times was significantly higher than after one 
doubling time (p<0.05, Dunnetfs test).
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7.4.4 The effect of spheroid size and incubation time on IUdR uptake
The relationship between the IUdR labelling index and incubation time is shown in Figure 
7.4. The incorporation of IUdR into small spheroids (100-200pm) increased with increasing 
incubation time (r=0.77, pO.OOl). The labelling index ranged from a mean of 76.5% (SE± 
1.9%) after one doubling time to 88.5% (SE±1.0%) after four doubling times. The linear 
regression equation relating labelling index (LI) and incubation time (T) in units of doubling 
times was LI = 72.8 + 4.0 T. Pairwise comparison of the groups showed that the labelling 
index after three and four doubling times was significantly higher than after one doubling 
time (p<0.05, Dunnetfs test).
The labelling index for large spheroids (700- 1000pm) also increased with increasing 
incubation time (r=0.82, pO.OOl), but was significantly lower than for small spheroids for 
all incubation times (p<0.005, Student's t test). It ranged from a mean of 29% (SE±2.3%) 
after one doubling time to 51% (SE±4.3%) after four doubling times. The linear regression 
equation relating labelling index (LI) and incubation time (T) for large spheroids was LI =
21.5 + 7.8 T. Pairwise comparison of the groups again showed that the labelling index after 
three and four doubling times was significantly higher than after one doubling time (p<0.05, 
Dunnetfs test).
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7.5 Discussion
The main purpose of these experiments was to investigate differences in uptake of IUdR for 
different modes of cell culture, and to determine the effect of prolonging the incubation time 
on overcoming any limitation on uptake imposed by proliferative heterogeneity. The results 
demonstrate that because of the insensitivity of antibody detection, it was necessary to 
determine the suitable concentration of non-radiolabelled IUdR required for measurement of 
the labelling index in different types of culture (monolayers and spheroids).
As shown in Figure 7.1, the IUdR labelling index in exponentially-growing monolayers 
achieved a maximum value of 97% at concentrations greater than 1 pM. By contrast, the 
labelling index in spheroids (Figure 7.2) continued to increase with IUdR concentration at 
least up to lOOpM. The reason for this difference is unclear. Possibly many cells in 
spheroids incorporate such a small proportion of the available IUdR that it falls below the 
threshold of detection by flow cytometry except at the highest concentration. It is possible 
that a higher labelling index would have been achieved by further increasing the concentration 
of IUdR. However, the purpose of these experiments was to find a suitable concentration 
for studying the effect of varying the incubation time, rather than the concentration yielding 
the maximum labelling index, and it was felt that lOOpM satisfied this purpose while 
remaining within a clinically realistic range.
IUdR is incorporated in DNA only during S-phase. Therefore a proportion of cells in which 
the cycle time exceeds the duration of incubation with IUdR would be expected to remain 
unlabelled with IUdR In exponentially growing monolayers, the IUdR labelling indices were
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unaffected by prolonged exposure to the drug (Figure 7.3). This suggests that few cells had 
a longer cycle time than the average, and hence that there is little heterogeneity in the 
duration of the cell cycle in monolayers.
Monolayers in plateau phase growth consist of cycling cells and cells in G0. This in vitro 
model is intermediate in complexity between exponentially growing monolayers and 
spheroids, which contain proliferating cells, necrotic cells, G0 cells and cells which are poorly 
oxygenated and nutrient-deprived. The effect of increasing incubation time (one to three 
doubling times) on monolayers in plateau phase of growth was an increase in the percentage 
of labelled cells from 62 to 85% (Figure 7.3). This is probably due to cells in G0 phase 
reentering the proliferative cycle.
Whereas in monolayer culture more than 95% of exponentially growing cells and 62 percent 
of plateau phase cells were labelled with IUdR after one doubling time (Figure 7.3), the 
labelling index in the small spheroids (100-200pm) was approximately 76% and for large 
spheroids (700-1000pm) 28% after one volume doubling time incubation (Figure 7.4). The 
results of the study in which IUdR concentration was varied confirm that there is an inverse 
relationship between the proportion of cycling cells and spheroid diameter. The percentage 
of cells labelled by IUdR after 52 hours incubation was higher for small spheroids (300- 
400pm) at concentrations of lOpM and lOOpM than for large spheroids (700-1000pm) (Figure 
7.2). As spheroids increase in size, the peripheral, well nourished cells continue to divide 
but the interior cells, lacking nutrients, often exit the cell cycle and enter G0 or non­
proliferating state (Olive and Durand, 1994). Therefore, it is expected that large spheroids 
will accumulate less IUdR due to the lower percentage of cells in S phase of the growth
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cycle.
Increasing the period of incubation with IUdR from one to four volume doubling times 
increased the proportion of cells that incorporated IUdR in small and large sizes of spheroids. 
This probably resulted from IUdR incorporation into cells which are proliferating less rapidly; 
for example cells existing in the hypoxic and nutrient deprived regions of large spheroids.
Hence, relative to monolayer culture, UVW cells growing as spheroids manifest a reduction 
in division rate among cycling cells as well as a reduction in the proportion of cells in cycle. 
The reduction in proliferative activity may be due to several factors, such as accumulation of 
metabolic waste products and decreased availability of oxygen and nutrients in the interior 
of spheroids (Olive and Durand, 1994).
IUdR targeted radiotherapy will be successful only if it results in the sterilisation of all 
tumour cells. Therefore, strategies must be designed to overcome the limitations imposed by 
proliferative heterogeneity, the presence of G0 cells and cells cycling very slowly. Such 
variation in proliferation was observed in the spheroid model. These experiments clearly 
illustrated that increased time of incubation with IUdR allows the maximum number of 
potentially cycling cells to incorporate IUdR.
One of the disadvantages of flow cytometry, as applied clinically, is the requirement for 
disaggregation of tissue into single cell suspensions and the corresponding loss of ability to 
relate kinetic parameters to tissue architecture. The effects of spheroid size and incubation 
time on labelling index, measured by autoradiography, is described in chapter 8.
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8.1 Aims
To examine the influence of proliferative heterogeneity and incubation time on cellular 
incorporation of [125I]IUdR.
8.2 Introduction
Although glioma does not metastasise to distant sites, it undergoes diffuse local spread and 
total surgical resection with a generous margin of adjacent normal tissue is rarely feasible. 
As discussed in Chapter 1, glioma is resistant to most cytotoxic drugs and, while some 
benefit has been reported with radiation treatment (Leibel et al., 1994), external beam 
radiotherapy is limited by normal tissue tolerance.
An alternative possibility is the therapeutic use of DNA-targeted Auger electron emitters 
such as 123I or 125I, bound to IUdR. Compared with non-radiolabelled cytotoxic drugs 
which are also thought to operate through interaction with DNA, radioiodinated IUdR may 
be, molecule for molecule, between 1000 and 100,000 times more potent (Humm and 
Charlton, 1989). The effectiveness of locoregional administration of this agent has been 
demonstrated in rodent models of gliosarcoma (Kassis, 1994), meningeal carcinoma (Kassis 
and Adelstein, 1996) and ovarian ascites (Baranowska-Kortylewicz et al., 1991). As few 
cells are proliferating in normal brain tissue, treatment with a proliferation-specific agent 
with high cytotoxic potency should be therapeutically beneficial.
Since IUdR is incorporated into the DNA only of those cells in S-phase, a major limitation 
to the efficacy of the radiopharmaceutical will be the presence of non-dividing cells in the 
targeted tumour. It is important that the effect of proliferative heterogeneity on IUdR
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targeted therapy should be evaluated because theoretical calculation suggests that this could 
be the dominant factor in the efficacy of treatment (O’Donoghue and Wheldon, 1996). 
Multicellular tumour spheroids as previously described in section 2.4, are a well- 
established model of prevascular microtumours that provide a means of studying the 
intratumour distribution of therapeutic agents and of determining the effect of alternative 
schedules of administration on cellular incorporation.
In this chapter, an autoradiographic technique using [125I]IUdR is described as a means of 
studying IUdR incorporation at different times and depths within multicellular glioma 
spheroids of a range of sizes. Cellular uptake of IUdR was compared with labelling for 
the proliferation marker Ki67. These investigations have suggested strategies to overcome 
the incomplete sterilisation of tumour cells which would result from the administration of 
a single dose of IUdR incorporating an Auger electron emitter.
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8.3 Materials and methods
Cells were cultured as monolayers and as spheroids as described in section 4.1 and 4.4.
8.3.1 Spheroid growth and size determination
Spheroid growth rate and size was determined as described in section 5.2.3.
8.3.2 Uptake of r125IHUdR by UVW monolayers
UVW cell monolayers in exponential growth were incubated in chamber slides with 
0.06MBq/ml of no-carrier-added [125I]IUdR for 44 hours (the doubling time for 
exponentially growing cells). [125I]IUdR was prepared according to the method described 
in section 4.7.
After washing several times with PBS to remove unbound radioactivity, cells were fixed 
with 50% (v/v) methanol / 50% (v/v) acetone. Slides were then subjected to Ki67 
labelling and autoradiography as described below.
8.3.3 Uptake of r125I!IUdR by UVW spheroids
Cell aggregates of approximately 100 pm diameter, were transferred to spinner flasks 
containing 150 ml of medium. The contents of the vessels were equilibrated with a 
mixture of 5% C 02 and 95% air for 3 min. The flasks were sealed and placed on a 
magnetic stirrer platform in a hot room at 37°C. Half of the medium was changed 3 times
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per week. After 2-6 weeks of growth, spheroids of 150pm to 1000pm diameter were 
transferred from the spinner flask into 50 ml tubes, each containing 10 ml of medium with 
0.06 MBq/ml of [125I]IUdR. Each tube contained 10-20 spheroids, depending on size.
After equilibration with 5% C 02 the tubes were placed on a roller shaker (Luckham, Ltd, 
Sussex) and incubated at 37°C for either 52 or 104 hours, i.e. one or two multiples of the 
initial volume doubling time calculated as described in section 5.2.3. The spheroids were 
then washed several times in culture medium until no further soluble radioactivity could 
be eluted. They were embedded in mounting medium on cork discs, and frozen by 
cooling in liquid nitrogen. The time between the end of the incubation period and freezing 
was 120 min. Sections (5 pm) were cut in a cryostat (Bright) at -20°C and thawed onto 
silanised slides. After drying at room temperature, the sections were stored desiccated at 
-20°C.
8.3.4 Ki67 staining
Ki67 is a nuclear antigen expressed during the Gls S, G2 and M phases of the cell cycle, 
but absent in the G0 phase. Immunocytochemical staining for Ki67 was used to evaluate 
the growth fraction in monolayers and different size of spheroids.
The Ki67 antigen was labelled in spheroid sections and monolayers by a conventional 3- 
step streptavidin-biotin-peroxidase system. Sections were removed from storage, warmed 
to room temperature, and fixed in 1% (v/v) formaldehyde in PBS. After 3 x 10 min. 
washes in PBS, non-specific binding was blocked with PBS containing 25% (v/v) swine 
serum and 25% (v/v) human serum for 10 min. This was replaced by the primary
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antibody (Dako, Ltd, UK) or non-immune rabbit immunoglobulins as a negative control, 
both diluted in PBS containing 10% (v/v) of each blocking serum. After one hour the 
primary antibody was washed off with 3 changes of PBS over 15 min., and the sections 
were incubated for 30 min with a 1:400 dilution of the secondary antibody, biotinylated 
swine anti-rabbit immunoglobulins (Dako, Ltd, UK), in the same diluent (initial 
concentrations are given in section 4.10). After 3 washes in PBS over 15 min., the 
sections were incubated with the streptavidin-biotin-peroxidase complex diluted in PBS for 
30 min. After further washes in PBS, the peroxidase signal was developed with a 10 min. 
incubation in 0.05% (v/v) diaminobenzidine tetrahydrochloride containing 0.01% H20 2 
(v/v) in PBS.
8.3.5 Autoradiography
Following Ki67 staining, slides were dipped in a 1:1 dilution of Kodak NTB-2 emulsion 
(Kodak, IBI Limited, England) in distilled water at 43°C. After drying, sections were 
exposed in light-proof desiccating boxes for 92 hours. Sections were developed in 1:1 
dilution of Kodak D19 developer at 10°C for 4 min. After a brief wash in distilled water, 
the emulsion was fixed in Kodafix (Kodak, IBI Limited, England) for 5 min. The slides 
were washed and counterstained with haematoxylin before dehydration through graded 
ethanols before being mounted in DPX synthetic resin mountant (BDH Laboratory 
Supplies).
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8.3.6 Measurement of IUdR and Ki67 labelling indices
Slides were examined using an Olympus BH2 microscope and an Imaging Research MCID 
image analysis system. All measurements were performed in equatorial sections of 
spheroids, which were identified by examination of serial sections and selecting the section 
in which the apparent diameter was at a maximum. The diameter of each spheroid was 
estimated by taking the mean of the maximum and the perpendicular to the maximum 
diameter in the equatorial section. Only spheroids in which these orthogonal diameters 
differed by less than 10% were included in the analysis.
UVW glioma spheroids with a diameter >= 300pm invariably showed a central core 
characterised by a complete absence of Ki67 and IUdR labelling, surrounded by an outer 
shell containing proliferating cells (Figure 2a), whereas those with a diameter of less than 
250 microns had no quiescent core (Figure 2b). The diameter of the quiescent core, if 
present, was measured in an equatorial section in the same manner as the spheroid 
diameter.
A single observer classed cells as either labelled or unlabelled for IUdR and Ki67. Cells 
were deemed to be positive for IUdR labelling if there were 10 or more silver grains 
overlying the nucleus. IUdR and Ki67 labelling indices were measured by counting the 
number of labelled nuclei and expressing this as a percentage of the total number of 
nuclei in predefined regions of the spheroid sections. Both IUdR and Ki67 labelling 
indices were calculated for either the whole section (in the absence of a quiescent core) 
or the whole proliferating rim of tissue (in the presence of a core). We refer to these 
values as “total” labelling indices. Additionally, regional IUdR labelling indices were 
calculated for concentric tissue layers, consisting of an outer layer extending from the
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surface of the spheroid to a depth of 25pm, a middle layer extending from 25pm to 50pm, 
and an inner layer extending from 50pm to 75pm from the surface. In the small number 
of sections in which the thickness of the proliferating rim was less than 75pm, the inner 
layer extended from 50pm to the edge of the quiescent core.
Differences between IUdR labelling indices for the two periods of incubation, and 
differences between Ki67 and IUdR labelling indices, were assessed by Student’s unpaired 
t test and paired t test respectively.
8.4 Results
UVW glioma monolayers in exponential growth showed a Ki67 labelling index of 93% 
±0.65% (SE) and an IUdR labelling index of 91% ±1.29% (SE) (mean of 8 slide 
chambers). Figure 8.3.2 shows the total IUdR labelling index in spheroids after 
incubation for 52 and 104 hours, and the corresponding Ki67 index, as a function of 
spheroid diameter. All labelling indices decreased with increasing spheroid diameter. 
For spheroids of less than 300 pm diameter, there was no significant difference between 
the IUdR labelling indices for 52 and 104 hours incubation, whereas for larger spheroids 
the longer incubation time increased labelling. The Ki67 labelling index was greater than 
both IUdR labelling indices for all sizes of spheroids.
There were strong correlations between the Ki67 and IUdR labelling indices for both 52 
and 104 hour incubations (r=0.95, pO.OOl and r=0.86, pO.OOl respectively) as shown in 
Figure 8.3.3. For the shorter period of incubation the relationship was LIIUdR = 1.09 X 
LIKi67 - 21, and for the longer period LIIudR = 1.08 X LIKi67 - 12.
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Figure 8.3.4 shows the IUdR labelling indices in each of the three 25pm layers as a 
function of spheroid diameter. The results can be summarised qualitatively as follows:
a) For any given spheroid diameter, the labelling index decreased with increasing depth 
within the spheroids.
b) The reduction in the labelling indices with increasing spheroid diameter occurred in all 
layers, but was more marked at depths greater than 25pm (middle and inner layers) than 
in the outer layer.
c) The effect of increasing the IUdR incubation time was greatest in the middle and inner 
layers of 300-400 pm diameter spheroids, where a doubling in the number of labelled 
cells was observed.
Even the highest regional IUdR labelling index (60-70%), achieved in the outer layer of 
small (<300 pm)spheroids was substantially lower than the index achieved in monolayers.
1 5 8
Figure 8.3.1. Sections of (a) 1000 pm diameter and (b) 250 fim diameter spheroids, 
showing cells labelled with both Ki67 (brown stain) and IUdR (black grains) or with Ki67 
alone, and unlabelled cells (haematoxylin counterstain). Scale bar =100  pm.
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Figure 8.3.3 The relationship between Ki67 and IUdR labelling indices for 52 and 
104 hour incubation periods. The equations of the linear regression lines are given 
in the text.
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Figure 8.3.4. Regional IUdR labelling indices for 52 and 104 hours incubation as a 
function of spheroid diameter in (a) outer, (b) middle and (c) inner 25pm cell layers. For 
the outer and middle layers, the two labelling indices were significantly different for each 
of the four largest size groups (p<0.05, unpaired t test). For the inner layer, the difference 
was significant only for the size groups 300-399pm and 400-499pm (p<0.01).
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8.5 Discussion
The purpose of this study was to assess the limitations to IUdR-targeted Auger electron 
therapy for glioma imposed by heterogeneity of cellular proliferation. The model chosen 
for this investigation was the human glioma cell line UVW cultured as multicellular 
spheroids. The growth characteristics of spheroids are similar to those of solid tumour 
nodules: composed of dividing cells close to the capillaries, adjacent non-proliferating cells 
and more distant necrotic regions (Carlsson and Nederman, 1989).
As has been observed for other cell lines (Wheldon et al., 1985; Olea et al., 1992), UVW 
glioma spheroids initially grew exponentially but then underwent a progressive reduction 
in growth rate, and this pattern showed a good fit to a Gompertzian equation as was shown 
in section 5.2.3. The spheroids developed a well-defined core in which Ki67 and IUdR 
labelling was completely absent, which was observed when they reached a diameter of 
250-300 microns. In spheroids of numerous other cell types, it has been reported that 
central necrosis occurs at a distance of 50-300 microns from the periphery, depending on 
cell type and substrate concentrations in the media (Sutherland, 1988). Experiments in 
which cell layers were stripped progressively from spheroids suggest that the necrotic 
region is surrounded by cells with little or no proliferative activity and clonogenic capacity 
(Freyer and Sutherland, 1980). Although it is uncertain whether the core of large UVW 
spheroids contained cells that were necrotic, irreversibly damaged, merely quiescent or a 
combination of all of these, the fact that proliferation is confined to a superficial rim of 
cells is consistent with findings in other spheroid models.
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The rim of proliferating tissue represented a decreasing proportion of total spheroid volume 
with increasing spheroid diameter, which partially accounts for the decreasing gradient of 
the spheroid growth curve. Other factors that may contribute to limitation of growth 
include reduced rates of cell division and increased cell death. It has recently been shown 
that a 3-dimensional cellular growth configuration is characterised by an enhanced 
tendency to apoptosis relative to monolayer cell culture (Rak et al., 1995). The relative 
contributions of these factors are of great importance to the potential efficacy and optimal 
mode of administration of cycle-specific therapy.
The results of the present study indicate that, in this model, there is an inverse relationship 
between the number of cycling cells, as assessed by Ki67 labelling, and spheroid diameter. 
Whereas in monolayer culture more than 90% of exponentially growing cells stained 
positively with Ki67, the growth fraction in the smallest spheroids studied was 
approximately 70% and this fraction decreased progressively with increasing spheroid size. 
For the largest spheroids, only 40 per cent of cells in the proliferating rim were cycling.
Ki67 labelling provides information about the proportion of cells in cycle, irrespective of 
phase, at the time of fixation, whereas IUdR is incorporated in DNA only during S-phase. 
Hence a proportion of any cells in which the cycle time exceeds the duration of incubation 
with IUdR would be expected to remain unlabelled with IUdR while still expressing the 
Ki67 antigen. In exponentially-growing monolayers, the IUdR and Ki67 labelling indices 
were essentially equal after incubation with IUdR for one doubling time. This suggests 
that few cells had a longer cycle time than the average, and hence that there is little 
heterogeneity in the duration of the cell cycle in monolayers.
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IUdR labelling indices in spheroids after incubation for 52 hours (the doubling time of the 
initial monoexponential growth phase) were significantly lower than the corresponding 
Ki67 labelled fraction. This suggests that, of the cycling fraction of cells, a considerable 
proportion had a cycle time longer than 52 hours. Hence, relative to monolayer culture, 
UVW cells growing as spheroids manifest a reduction in division rate among cycling cells 
as well as a reduction in the proportion of cells in cycle. In addition, the present study 
demonstrates that IUdR incorporation is further reduced at depth within the proliferating 
region of spheroids relative to the superficial cell layers. Similar findings for 
radiolabelled thymidine incorporation were reported for spheroids derived from human 
breast carcinoma cell line MCF-7 (Olea et al., 1992). The reduction in proliferative 
activity with depth, and the complete absence of proliferation within the central core, may 
be due to several factors, including decreased availability of oxygen and nutrients, and 
accumulation of metabolic waste products, growth-inhibitory agents and hydrogen ions 
(Groebe & Mueller-Klieser, 1996).
Another factor that could, in principle, affect the spatial and temporal variation in labelling 
index is the rate at which IUdR penetrates the interior of spheroids. Thymidine, of which 
IUdR is an analogue, diffuses readily through cell membranes and has been shown to 
penetrate spheroids to a depth of 300 pm within 1 min (Nederman et al., 1988). Another 
halogenated thymidine analogue, BUdR (bromodeoxyuridine), penetrated 390 pm from the 
surface of human glioma fragments after 1 hour and acheived a maximum pentration of 
0.8 mm (Morimura et al., 1991). It is therefore unlikely that limited penetration of IUdR 
was a significant factor in the present study in which we observed a gradient in labelling 
index within 75 pm of the surface of spheroids after a minimum incubation period of 52 
hours.
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Increasing the period of incubation with IUdR from 52 to 104 hours increased the 
proportion of cells that incorporated IUdR in most size classes, although the IUdR labelling 
index remained lower than the corresponding index for Ki67. It is therefore likely that 
a higher uptake of IUdR could be achieved by further prolongation of the incubation time. 
This is particularly true for the treatment of cells which are proliferating less rapidly as 
exemplified by cells existing in the hypoxic and nutrient deprived regions of large 
spheroids.
The success of curative targeting strategies is governed by the ability to sterilise all 
clonogens. Therefore, therapeutic regimes must be designed to overcome the limitations 
imposed by proliferative heterogeneity, including the presence of viable tumour cells which 
are temporarily out of cycle or cycling very slowly. Such conditions were apparent using 
this spheroid model, in which substantial variation in proliferative fraction was observed. 
This study clearly demonstrates that increased time of incubation with IUdR partially 
overcomes this obstacle. The optimal benefit from radioiodinated IUdR therapy is likely 
to be obtained by prolonged exposure to the drug so that the maximum number of 
potentially cycling cells will incorporate the Auger emitter. Possible modes of delivery 
include multiple injection, slow release from biodegradable polymer implants (Whately et 
al., 1995) and continuous infusion via osmotic pumps. However, it is possible that 
practical limitations to the duration of therapy will preclude the targeting of every potential 
clonogen by IUdR therapy alone. Consequently, modification to this promising 
therapeutic approach must be considered, such as the use of radiohalogen conjugates with 
longer range emissions which may eradicate adjacent, untargeted cells by crossfire 
irradiation.
1 7 0
Theoretical considerations of proliferative heterogeneity imply that benefit may be obtained 
from use of both short-range and long-range emitters (e.g. 123I and 131I) with external beam 
irradiation (O’Donoghue and Wheldon, 1996). The optimal strategy will depend on the 
magnitude and nature of the proliferative heterogeneity in the target tumour. The 
comparative cytotoxicity of short-range and long-range radionuclide conjugates of 
deoxyuridine is discussed in chapter 9.
1 7 1
Chapter 9
Differential cytotoxicity of alternative 
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9.1 Aims: To compare the therapeutic potential of IUdR labelled with different 
radioisotopes (123I, ,25I and 131I) using glioma cells cultured as monolayers in exponential 
or plateau phase of growth and as spheroids.
9.2 Introduction
123I and 125I decay to emit highly radiotoxic Auger electrons whose effective range, in 
terms of DNA damage, is a few nanometers (Martin and Haseltine., 1981). In order to 
kill cells, these radionuclides must be incorporated into DNA (Kassis et al., 1987a) or be 
closely associated with it (Schwartz et al., 1996). Therefore IUdR, conjugated to 
radioiodine, has great potential as a radiotherapeutic agent which is capable of selectively 
targeting dividing cells. This cycle-specific treatment strategy is especially attractive for 
the elimination of malignant glioma cells because, when administered intracranially, IUdR 
should be toxic to the tumour but have no adverse effect on normal, quiescent tissue of 
the central nervous system (Kassis et al., 1990).
Several in vitro studies have demonstrated the exquisite toxicity of 123I- and 125I-iodinated 
IUdR to dividing cells (Hofer and Smith, 1975; Makrigiorgos et al., 1989; Schneiderman 
and Schneiderman, 1996) and the effectiveness of locoregional administration of this agent 
has been shown in rodent models of gliosarcoma (Kassis, 1994), meningeal carcinoma 
(Kassis and Adelstein, 1996) and ovarian ascites (Baranowska-Kortylewicz et al., 1991). 
Recently, the incorporation of IUdR in a range of human tumours has been reported 
(Mariani et al., 1996a; Kassis et al., 1996; Mariani et al., 1996b; Macapinlac et al., 1996; 
Daghighian et al., 1996).
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A well-recognised limitation of treatment with IUdR labelled with Auger electron emitting 
radionuclides is the existence of a subpopulation of malignant cells which is not in the 
DNA synthetic phase of the cell cycle during the time of exposure to IUdR. Cells that 
fail to incorporate the IUdR into DNA will not be exposed to significant amounts of the 
highly localised energy deposition of Auger electrons. Possible means of overcoming this 
limitation include the use of prolonged or repeated exposures, and the use of other 
treatment modalities in combination with Auger electron therapy. One potential 
complementary therapeutic agent is the p-emitter [131I]IUdR. Although less cytotoxic to 
the targeted proliferation cells than [123I]IUdR or [125I]IUdR (Hofer and Hugues, 1971; 
Chan et al., 1976), the relatively long range of beta electrons results in the irradiation of 
neighbouring non-proliferating cells by the cross-fire or bystander effect (Wheldon and 
O'Donoghue 1997).
None of these investigations has directly addressed the limitation to efficacy of IUdR- 
targeted Auger electron therapy imposed by proliferative heterogeneity. Conventional in 
vitro cell monolayers do not exhibit the heterogeneity associated with solid tumours in 
vivo, but in the latter the study of cycle-specific effects is complicated by the separate 
issues of ensuring the delivery of the agent to all malignant cells and quantifying their 
exposure to it. An alternative model system is provided by tumour spheroids. The non- 
uniform uptake of IUdR by multi-cellular tumour spheroids and how this may be partially 
overcome by prolonged incubation has been described in Chapters 7 and 8. This chapter 
describes the limitation on cell killing by DNA-targeted Auger electron radiotherapy in 
spheroids resulting from proliferative heterogeneity, and evaluates the use of [131I]IUdR 
as a complementary or alternative treatment.
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9.3 Materials and methods
9.3.1 Synthesis of radiolabelled IUdR
Radioiodinated (no-carrier-added) IUdR was prepared according to the method described 
in section 4.7.
9.3.2 Clonogenic assay
The effect of radioiodinated IUdR was determined upon the clonogenicity of UVW cell 
cultures treated in exponential growth phase, in plateau growth phase and growing as 
multicellular spheroids as described in section 4.8.
9.3.3 Incorporation of IUdR into DNA
Monolayer cells in exponential phase were incubated with a range of concentrations of 
[125I]IUdR (1.0 kBq/ml to 100 kBq/ml) for one doubling time (44 hours) at 37°C. 
Incorporation of [125I]IUdR into DNA was determined according to the procedure described 
in section 4.9.
9.3.4 Converting radioactivity to number of radioactive atoms
The number of molecules of each radioisotope that produce a given quantity of 
radioactivity was calculated using the equations: 
t1/2 = In2/A,
where t ]/2 is the radioactive half life in seconds and k  is the decay constant, and 
A = XN
where A is the radioactivity in Bequerels and N is the number of molecules.
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9.3.5 Statistical analysis
Cell survival for the three radiopharmaceuticals at a given concentration of radioactivity 
was compared using one-way analysis of variance together with Tukey’s method for 
pairwise comparisons between groups, which corrects significance levels for multiple 
simultaneous comparisons. Statistical significance was assessed at the 5% level.
9.4 Results
9.4.1 Clonogenic Assay
9.4.1.1 UVW monolayer cells in exponential phase
The survival fraction of cells in exponential growth is plotted as a function of initial 
radioactive concentration in the medium for [125I]IUdR, [123I]IUdR and [131I]IUdR in Figure 
9.1. The survival curves could be approximated by a monoexponential function of 
concentration (survival fraction = exp[-C/C37], where C represents concentration of 
radioactivity in the medium) but may not be directly comparable with D0 expressed in 
absorbed dose units, as in conventional survival curves. C37 is a constant equal to the 
concentration at 37% clonogenic survival). The slope (1/C37) and C37 for each survival 
curve, derived from the fitted monoexponential function, are given in Table 9.1. In terms 
of concentration of radioactivity, [125I]IUdR was the most potent and [131I]IUdR the least 
potent of the three agents.
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Radioisotope Slope (ml/ kBq) C37 (kBq/ ml)
[125I]IUdR -0.423±0.018 2.36
[123I]IUdR -0.102±0.004 9.75
[I31I]IUdR -0.053±0.006 18.9
Table 9.1 Slope (±SE) and C37 of survival curve of UVW monolayer cells in exponential 
growth incubated with radiolabelled IUdR for 44 hours.
Non-radioactive IUdR at a concentration of 1.2 nM, which is equivalent to the maximum 
molar concentration of radiolabelled IUdR employed in this study, was found to have no 
effect on cell survival as determined by the clonogenic assay. Incubation of UVW 
monolayer cells in Na125I or Na131I at a concentration of lOOkBq/ml also did not result in 
any measurable change in survival (Figure 9.2).
9.4.1.2 UVW monolayer cells in plateau phase
Figure 9.3 shows the survival fraction of monolayer cells in plateau phase following 
incubation with [125I]IUdR, [123I]IUdR, and [131I]IUdR. The survival curves consisted of 
two parts: an initial steep portion in which survival was dependent on concentration, and
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a region where survival was effectively constant for all concentrations of radioactivity 
above a certain level. The Auger emitters [123I]IUdR and [125I]IUdR were more effective 
than [131I]IUdR over the whole range of concentrations, although only the differences 
between [123I]IUdR and [131I]IUdR at 5, 10 and 20 kBq/ml were statistically significant 
(p<0.05). [123I]IUdR appeared to be more effective than [125I]IUdR over the concentration 
range 5-40 kBq/ ml, but the difference was not statistically significant at any concentration 
(p>0.05). A maximum of approximately 60% of cells were killed by [123I]IUdR and 
[125I]IUdR and 40% by [131I]IUdR.
9.4.1.3 UVW spheroids
Figure 9.4 shows the survival curves of spheroids after incubation with [125I], [,23I] and 
[131I]IUdR. Like the curves for plateau-phase monolayer cells, survival curves showed 
a dose-dependent region at low concentrations of all three radiopharmaceuticals, and a 
dose-independent region for high concentrations of [125I]IUdR and [I23I]IUdR. However, 
at concentrations greater than 40 kBq/ml, the survival curve for [131I]IUdR continued to 
decline with a reduced gradient.
Both [125I]IUdR and [123I]IUdR were significantly more effective than [131I]IUdR at doses 
up to and including 20 kBq/ml (p<0.05). However, in contrast to the results for 
monolayers, the survival curve for [,31I]IUdR crossed the curves for [125I]IUdR and 
[123I]IUdR, resulting in lower survival for [131I]IUdR than for the other 
radiopharmaceuticals at concentrations of 40 kBq/ml and above. This difference was 
statistically significant at 100 kBq/ml (p<0.05).
179
[125I]IUdR was more effective than [123I]IUdR over the whole concentration range, and this 
was statistically significant at concentrations of 1, 20 and 100 kBq/ml (p<0.05). The 
initial slopes of the three survival curves were similar to those for exponentially growing 
monolayers (Table 9.2)
Figure 9.5 shows the survival curve of spheroids after incubation with [125I]IUdR for 52 
and 104 hours. Like the curve for spheroid cells after incubation with [125I]IUdR for 52 
hours, 104 hours survival curves showed a dose-dependent region at low concentrations 
and a dose-independent region for high concentrations of [125I]IUdR. However, there was 
no significant difference in survival fraction at any concentration after 52 and 104 hours 
incubation.
Radioisotope Initial slope (ml/kBq)
[,25I]IUdR -0.616±0.090
[,23I]IUdR -0.096±0.009
[131I]IUdR -0.043±0.002
Table 9.2 Slope (±SEM) of the initial portion of the survival curves of the UVW 
spheroids incubated with radiolabelled IUdR for 52 hours.
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9.4.2 Comparison of survival and labelling index
The percentage of cells labelled by IUdR in the different conditions of culture as measured 
by flow cytometry or autoradiography, are compared with the percentage of cells killed 
by the three radiopharmaceuticals in Table 9.3. The percentage of cells killed by 
[125I]IUdR at the maximum concentration studied, as determined by the clonogenic assay, 
was of a similar magnitude to the labelling index as determined by flow cytometry for the 
corresponding conditions of culture. There was also good agreement between the 
labelling index and the percentage of monolayer cells killed by [123I]IUdR, although this 
radiopharmaceutical was somewhat less effective in spheroids than the flow cytometric 
labelling index would predict. [131I]IUdR killed a smaller percentage of cells in 
monolayer growth and a higher percentage in spheroids than were labelled with IUdR 
according to the flow cytometric measurements.
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Culture phase Labelling 
index (%) 
by flow 
cytometry
Labelling 
index (%) 
by auto­
radiography
Maximum 
% cells 
killed
125 j
Maximum 
% cells 
killed
123 j
Maximum 
% cells 
killed
131 j
Exponential
monolayer
97±1 91±1 98±1 96±1 91±1
Plateau
monolayer
62±2 ND* 60±2 56±16 41±12
Spheroids 76±7 59.2±1.7 72±1 55±4 87±1
Table 9.3 Comparison between labelling index studied by flow cytometry, autoradiography 
and cell killing by clonogenic assay (mean±SEM) at the maximum concentrations studied.
* ND= Not determined
9.4.3 Incorporation of IUdR into DNA
The uptake of [,25I]IUdR into DNA was linearly related to the concentration of the agent 
in the medium over the range studied (Table 9.4).
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Concentration of 
activity (kBq/ml)
D N  A - a s s o c i a t e d  
activity per cell (mBq)
1.0 0.50±0.01
10 5.2±0.4
100 55.6±1.65
Table 9.4 Uptake of [125I]IUdR into UVW cells in exponential monolayer growth 
(mean±SEM) for different concentrations of the radiopharmaceutical in the medium.
I z . j i z i j 131I
44 hour incubation 
(monolayer cultures)
1.00 0.26 0.91
52 hour incubation 
(spheroid culture)
1.00 0.21 0.90
Table 9.5 Number of decays per cell for 123I and 13,I relative to 125I, integrated over 
incubation periods of 44 and 52 hours, given equal initial concentrations of radioactivity 
(in the form of radioiodinated IUdR) in the medium, calculated according to the formula 
derived by Makrigiorgos et al. (1989).
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Figure 9.1 Surviving fraction of UVW monolayer cells in exponential growth 
phase after incubation with [125I] IUdR , [123I] IUdR and [l31I]IUdR. Each point 
represents the mean ±SEM of three experiments.
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Figure 9.2 Surviving fraction of UVW monolayer cells in exponential growth 
phase after incubation with Na[12M] and Na[13lI]. Each point represent the mean 
±SEM of three experiments.
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Figure 9.3 Surviving fraction of UVW monolayer cells in plateau growth phase 
after incubation with [l25I] IUdR , [123I] IUdR and [13lI]IUdR. Each point presents 
the mean ±SEM of three experiment
186
0  2 0  4 0  6 0  8 0  100  120
Dose (kBq/ml)
Figure 9.4 Surviving fraction of UVW spheroids after incubation with [12:1 IJIUdR, 
[123I] IUdR and[131I]IUdR. Each point represents the mean ±SEM of three 
experiments.
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Figure 9.5 Surviving fraction of spheroids after 52 and 104 hours incubation 
with [ l25I]IUdR. Each point represents the mean ±SEM of three experiments.
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9.5 Discussion
The local administration of 125I- or 123I-labelled IUdR for DNA-targeted therapy of glioma, 
is a potential means for the selective eradication of residual malignant cells following 
surgical resection. However, due to the extremely short range of the Auger electrons 
emitted by 125I or 123I, only those tumour cells which are engaged in DNA synthesis during 
the time of exposure to the radiopharmaceutical will be sterilised. Accordingly, strategies 
must be devised which are capable of overcoming the limitations imposed by proliferative 
heterogeneity (Neshastehriz et al., 1997). In this study, we have assessed the relative 
efficacies of three radioiodoconjugates of deoxyuridine: two ultra-short range Auger 
electron emitters (125I and 123I) and one long-range P-emitter (131I).
The results of the toxicity studies have been expressed in terms of the initial concentration 
of radioactivity in the culture medium, rather than the number of radioactive decays per 
cell from DNA-incorporated IUdR. The justification for this approach is that the initial 
concentration is directly measured and is a readily-understood variable in a clinical 
context. The number of decays per cell is important for microdosimetry calculations, but 
this was not the aim of this study. Furthermore, it is clear from the autoradiographic 
studies of IUdR incorporation in spheroids (Chapter 8), that the incorporated radioactivity 
is highly variable from cell to cell in this mode of culture, which reduces the utility of an 
average value for quantitative microdosimetric purposes. However, to estimate the 
relative number of decays per cell for the three radioisotopes for the purpose of 
comparison with other studies, the formula derived by Makrigiorgos et al. (1989), may be 
used:
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Cumulative number of decays per cell = kC0[l-(l+A.T)e'A,T]/X2
where k is a constant representing the rate of uptake of radioactivity into cells relative to 
the concentration in the medium, C0 is the initial concentration of extracellular 
radioactivity, X is the physical decay constant for the radionuclide in question, and T is 
the incubation period. This formula assumes that the rate of incorporation of IUdR is 
proportional to concentration and is linear with time over the incubation period. It does 
not include decays after the end of incubation. Table 9.5 shows the relative number of 
decays for the three radioisotopes according to this formula for incubation periods of 44 
and 52 hours, given equal initial concentrations of radioactivity in the medium.
In exponentially-growing UVW monolayers, incorporation of [125I]IUdR was directly 
proportional to extracellular concentration, which is consistent with the findings of other 
authors (Kassis et al., 1987b; Makrigiorgos et al., 1989). All three agents yielded 
exponential survival curves with no evidence of a shoulder. For [125I]IUdR and [123I]IUdR 
this is also consistent with previous studies (Kassis et al., 1987b; Makrigiorgos et al., 
1989; Schneiderman and Schneiderman, 1996), although [13,I]IUdR has been reported to 
produce a curve with a shoulder in other cell lines (Hofer and Hughes, 1971; Chan et al., 
1976). This may reflect differences in the efficacy of DNA repair mechanisms in 
different cell lines and under different experimental conditions.
The initial concentration of radioactivity required to achieve a given level of cell kill was 
approximately four times greater for 123I than 125I. However, the cumulative number of 
radioactive decays per cell for DNA-incorporated IUdR, as estimated by applying the 
decay correction factor of 0.26 (Table 9.5), was approximately equal for the two Auger 
electron emitters. In Chinese hamster V79 lung fibroblasts, Makrigiorgos et al. (1989)
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observed a twofold difference in cytotoxic efficacy (on the basis of decays per cell), in 
favour of [125I]IUdR for the same two radioiodinated drugs. It is again possible that the 
different result in the present study is related to differences in the cell lines, incubation 
periods and other experimental variables.
The radioactive concentration required to reduce cellular survival to 37% was eight times 
larger for 13,I than for 125I in exponentially growing monolayers. This is comparable with 
the elevenfold difference in effectiveness for these agents previously reported in L1210 
lymphoid leukaemia cells (Hofer and Hughes, 1971) and Chinese hamster V79 lung 
fibroblasts (Chan et al., 1976). The superiority of 125I and 123I relative to 131I for the 
treatment of rapidly-proliferating single cells is due to the short range of the Auger 
electrons and their efficient absorption in the nuclei of single cells.
Using Tables 9.1 and 9.4, the estimated decay-corrected activity per cell corresponding to 
a 37% survival level (C37) was 1.3, 5.4 and 10.4 mBq/cell for [l25I]IUdR, [,23I]IUdR and 
[131I]IUdR respectively. The number of IUdR molecules that would be incorporated 
through the salvage pathway into DNA, calculated by using the equations described in 
section 9.3.4 from C37, were 9785, 371 and 10448 molecules per cell for [125I]IUdR, 
[123I]IUdR and [131I]IUdR respectively. This may be compared with the values of 3915 
and 356 molecules per cell for [,25I]IUdR and [123I]IUdR in Chinese hamster ovary (CHO) 
cells obtained by Schneiderman and Schneiderman (1996). No saturation was observed 
in the cytotoxicity of the three agents in rapidly-proliferating monolayer cells, and it was 
possible to achieve a cell kill of greater than 90% by administration of a sufficiently high 
dose of radiopharmaceutical. This is in agreement with the BrdU labelling index as 
determined by flow cytometry and autoradiography described in Chapters 7 and 8
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respectively which indicates that almost all cells in these conditions are in cycle and 
capable of incorporating the agent during DNA synthesis. However, under more 
clinically realistic conditions of tumour cell growth, the situation is more complex: a 
proportion of cells may be out of cycle or not actively involved in DNA synthesis during 
the period of exposure to IUdR, and this would be expected to limit the efficacy of DNA- 
targeted Auger electron emitters. The results in plateau phase monolayers and in 
spheroids support this prediction.
As was previously discussed, monolayers in plateau phase growth consist of cycling cells 
and cells in G0. This in vitro model is intermediate in complexity between exponentially- 
growing monolayers (composed almost entirely of dividing cells) and spheroids, which 
contain proliferating cells, necrotic cells, G0 cells and cells which are poorly oxygenated 
and nutrient-deprived. In the treatment of confluent UVW monolayers in plateau phase 
of growth, the effectiveness of all three radioiodoanalogues of IUdR was attenuated by the 
presence of non-cycling cells. The percentage of cells killed increased with the 
concentration of each agent up to a maximum of approximately 60% in the case of the 
Auger electron emitter conjugates, and 40% in the case of [131I]IUdR. The cell kill for 
the more potent agents corresponded closely with the labelling index determined by flow 
cytometry, supporting the concept of the lethality of DNA incorporation of Auger electron 
emitters.
In the spheroid model, both [125I]IUdR and [123I]IUdR showed a strongly dose-dependent 
effect at low concentrations, but their cytotoxicity reached a maximum of approximately
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55-70%, and did not further increase at activity concentrations greater than 40 kBq/ml. 
This confirms that only a proportion of cells in this growth model are vulnerable to 
sterilisation by Auger electrons. There was a small but statistically significant difference 
in clonogenic survival between spheroids exposed to high concentrations (>40 kBq/ml) of 
[125I]IUdR and [123I]IUdR. Even allowing for the expected fivefold difference in the 
number of decays per cell (Table 9.5), [125I]IUdR at an extracellular concentration of 20 
kBq/ml was more effective than [123I]IUdR at 100 kBq/ml. Hence, the difference in 
survival is difficult to explain if it is assumed that all cells that incorporate a significant 
fraction of the available activity for either agent at the highest concentration are killed. 
Closer agreement was observed between the labelling index as measured by flow 
cytometry and autoradiography in spheroids and the proportion of cells killed by [125I]IUdR 
than by [123I]IUdR, suggesting that some factor may be limiting the cytotoxic effect of the 
latter agent in this model.
In contrast to the Auger emitters, [131I]IUdR was progressively more toxic at increasing 
doses in the spheroid model. This is consistent with microdosimetric expectations: 
whereas most of the decay energy of 1311 incorporated in monolayers is dissipated above 
and below the plane of the cells, p-radiation cross-fire is effective in cellular aggregates. 
Hence, in addition to DNA-synthesising cells, adjacent non-cycling cells suffer the effects 
of P-decay energy. The fact that the steepest part of the survival curve for [131I]IUdR 
occurred at low concentrations, suggests that its cytotoxic effect on cycling cells outweighs 
its effect on non-cycling cells within the range of concentrations studied, although it is 
likely that higher concentrations of [131I]IUdR would prove more effective in killing non­
cycling cells within spheroids.
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It is clear that there are major differences in the shape of survival curves for cells in 
spheroid culture following exposure to the different forms of radioiodinated IUdR and to 
external beam irradiation (Chapter 6). These differences are broadly in accordance with 
the expected effect of the different types of radiation involved. Although spheroids were 
more resistant than monolayers to external beam treatment, the survival curves in both 
cases had a classical linear-quadratic form, and there was no evidence of a lower limit to 
cell survival at increasing doses. By contrast, the response of spheroid cells to 
radioiodinated IUdR was sharply differentiated both from that of monolayers exposed to 
the same agent and from that of spheroids subjected to gamma irradiation. The Auger 
electron emitters [125]IUdR and [123I]IUdR, as expected, were capable of sterilising only 
the cells undergoing DNA synthesis during the period of incubation, while the [13,I]IUdR 
survival curve at high concentrations showed a decline consistent with a cross-fire effect 
which was absent from the curves for [125I]IUdR and [123I]IUdR.
The absorbed fraction of decay energy of 131I (0.11 g Gy/MBq/h), uniformly distributed 
in tissue spheres of 100pm diameter, has been calculated to be approximately 10% 
(O'Donoghue et al., 1995). If the average rate of uptake of IUdR by cells in spheroids 
were the same as in monolayers (Table 9.4), and assuming a cellular density of 5xl08 cells 
per gram, the cross-fire radiation dose to spheroids during incubation with [131I]IUdR at 
a concentration of 100 kBq/ml would be approximately 8 Gy. This gives a surviving 
fraction of 0.13 (see Figure 9.4). The true average rate of uptake of IUdR by cells in 
spheroids would be substantially smaller in spheroids than in monolayers because of the 
presence of non-cycling and slowly-cycling cells, and, because of the highly non-uniform 
distribution of radioactivity, the radiation dose to individual cells is likely to vary
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considerably. Also, the radiation from 131I is given at low dose rate over one volume 
doubling time (52 hours) incubation. For comparison the external beam radiation dose 
to achieve a surviving fraction of 0.13 in UVW spheroids is approximately 6 Gy (see 
Figure 6.4). Therefore, the calculation dose from [131I]IUdR is in reasonable agreement 
with the external beam studies.
No significant difference was observed in the survival fraction of spheroids after one or 
two volume doubling times incubation with [125I]IUdR. This is consistent with the result 
obtained by autoradiography for the small size of spheroids described in Chapter 8. The 
labelling index as measured by flow cytometry over an exended range of incubation times 
showed a small enhancement, which would correspond to a predicted difference in survival 
fraction of approximately 4% in the present experiment. This small difference is within 
the confidence limits of the results of this study. The effects of prolonging the incubation 
time on the labelling index in different sizes of spheroid suggests that a limited increase 
in cell killing by [125I]IUdR or [123I]IUdR could be achieved by extending the period of 
exposure, particularly for larger spheroids (Chapters 7 and 8). However, the small 
gradients of the labelling index versus time curves suggests that 100% sterilisation of cells 
in spheroid culture is not realistically achievable by Auger electron emitters alone.
It is possible that the maximal therapeutic benefit may be derived from the use of 
'cocktails' of radioiodoconjugates of IUdR including both Auger electrons to kill cycling 
cells and the p-emitter 1311, at sufficiently high activity, to eliminate untargeted cells by 
cross fire. Nevertheless, the optimum agent or combination of agents for targeted
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radiotherapy of gliomas in vivo depends on several factors in addition to those addressed 
in this study. These include whether the number of molecules of the radiopharmaceutical 
that can be incorporated into tumour cells is a limiting factor, rather than the quantity of 
radioactivity. The former would favour the use of 123I rather than 125I since, in terms of 
the number of atoms incorporated per cell to induce a given reduction in clonogenic 
survival, it was many times more effective. By contrast, at equal activities, the longer- 
lived radioisotope, 125I, was superior. Other factors that would influence the choice of 
radioactive atom include the uptake of radiopharmaceutical by critical normal organs as 
well as rates of deiodination and escape from the intracranial space to the circulation. 
The short half life of ,23I is a further advantage in this respect. The effects of some of 
these variables is currently being investigated by researchers in the Department of 
Radiation Oncology using an in vivo glioma model system.
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Chapter 10 
Conclusions and future work
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Conclusions
Malignant glioma account for approximately 40% of all central nervous system 
malignancies. These are essentially localized neoplastic tumours that have to date defied 
most treatments and despite improved techniques, surgery has been shown to be unlikely 
to prolong patient survival. Unfortunately the tumour is also resistant to most cytotoxic 
drugs and while some benefit has been reported with radiation treatment, external beam 
radiotherapy is limited by normal tissue intolerance.
Due to fundamental problems such as limitation of current diagnostic techniques, 
localisation of malignant glioma and difficulty of total removal or effective sterilization of 
the tumour, the prognosis for patients has not improved greatly in the last 15 years. This 
low median survival of patients, motivates the search for alternative diagnostic procedures 
and treatment modalities that will allow selective killing of glioma cells.
In this study, human glioma continuous cell lines have provided useful models for the study 
of the in vitro behaviour of human malignant glioma. In vivo human gliomas exhibit 
heterogeneity of cell type, cell cycle status and irregular vascularisation. It is vital that 
these factors be taken into account when establishing a model system to investigate effective 
cell kill. One such tool, tumour spheroids, represent a useful in vitro model for the study 
of heterogeneity with respect to the effects of cytotoxic drugs and targeted radiotherapy on 
gliomas. Spheroids exhibit a histological structure similar to that of solid tumours. This 
holds for the distribution of vital and necrotic areas, and for the histologic appearance. It 
is a general finding that the degree of structural and functional differentiation in the primary 
tumour may be retained in spheroids rather than in conventional monolayer cultures. We 
therefore employed spheroids derived from glioma cell lines to evaluate the effect of
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proliferative heterogeneity of tumour cells on the therapeutic potential of the cycle-specific 
agent, radiolabelled IUdR.
The human glioma cell lines originally analyzed in this study were UVW, SB 18 and U251. 
They exhibited a heterogeneous range of phenotypic characteristics. The UVW cell line 
was regarded as the most satisfactory in vitro model because of its capability to grow as 
very large and regularly shaped spheroids. The latter characteristic was essential for our 
study of the effect of targeted radiotherapy on proliferative heterogeneity, which increases 
with spheroid size. This cell line was highly aneuploid and contained populations of cells 
which were sub tetraploid (74 chromosomes per genome).
We wished to determine the radiosensitivity of this cell line under different conditions of 
culture for comparison with the response to IUdR targeted radiotherapy. The effect of 
external beam irradiation on UVW cells was assessed in both monolayer and spheroid 
culture. The results indicated that UVW was a highly radioresistant cell line in both 
monolayer and spheroid cultures, with SF2 values of 0.55 and 0.83-0.93 (obtained fron 
clonogenic assay and growth delay) respectively, which placed this cell line at the resistant 
end of the radiosensitivity spectrum of cell lines.
Biologically targeted radiotherapy entails the preferential delivery of radiation to malignant 
cells by means of tumour-seeking delivery vehicles to which radionuclides can be 
conjugated. Once such vehicle, iodo-2'-deoxyuridine (IUdR), is a low-molecular-weight 
thymidine analogue that diffuses readily within tissues. When radiolabelled with an Auger 
electron emitter (e.g., 123I or 125I), it is highly toxic when incorporated into DNA. Since 
the majority of the cells within the CNS are nondividing, they do not incorporate IUdR into 
their DNA, allowing the agent to be taken up selectively by dividing malignant cells
199
(Halperin et al., 1988).
Heterogeneous uptake of radiolabelled IUdR in glioma which are comprised of cells in 
different stages of the cell cycle, can lead to under dosing of untargeted cells if there is 
insufficient cross-fire irradiation from targeted dividing cells. This problem will be 
minimal when the bound radionuclide is a long range P-emitter such as 131I but the dosage 
to surrounding normal tissue may be substantial. Conversely, strategies based upon the 
incorporation of ultra short range Auger electron emitters should reduce damage to adjacent 
organs but may fail to sterilise all tumour clonogens if cellular uptake is not completely 
uniform.
In order to assess the IUdR labelling index, we used non-radiolabelled IUdR, detected by 
anti-BUdR/IUdR monoclonal antibody in conjunction with flow cytometry. The uptake of 
non-radiolabelled IUdR was examined by studying different sizes of UVW human glioma 
spheroids and monolayer cell cultures in exponential and plateau phases, to assess the effect 
of proliferative heterogeneity. Whereas in monolayer culture more than 95% of 
exponentially growing cells and 62% of plateau phase cells were labelled with IUdR after 
one doubling time, the labelling index in the small spheroids (100-200pm) was 
approximately 76% and for large spheroids (700-1000pm) was 28% after one volume 
doubling time incubation (52 hours). The results of the study in which IUdR concentration 
was varied, confirm that there is an inverse relationship between the proportion of cycling 
cells and spheroid diameter. The percentage of cells labelled by IUdR after one volume 
doubling time incubation was higher for small spheroids (300-400pm) at concentrations 
of lOpM and lOOpM than for large spheroids (700-1000pm).
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Increasing the period of incubation with IUdR from one to four volume doubling times 
increased the proportion of cells that incorporated IUdR in small and large sizes of 
spheroids.
We analysed the labelling index in different sized spheroids by flow cytometry, however 
one of the disadvantages of this procedure is the requirement for disaggregation of tissue 
into single cell suspensions. This results in the loss of ability to relate kinetic parameters 
to tissue architecture. We therefore studied the effect of spheroid size and incubation time 
on labelling index by autoradiographic assessment. This represent the proliferative state 
of cells in a glioma in vivo.
Autoradiographic identification of labelled cells indicated that nuclear incorporation of 
[125I]IUdR decreased markedly with increasing size of spheroid. IUdR incorporation was 
maximal in the surface layer of cells and decreased with depth within the spheroids.
Radiopharmaceutical uptake corresponded closely to the regions of cell cycling as indicated 
by staining for the nuclear antigen Ki67. The uptake of drug was enhanced by increasing 
the duration of incubation from 52 hours to 104 hours. These observations suggest that 
significant sparing of non-cycling malignant cells would result from treatment delivered as 
a single injection of radiolabelled IUdR. To achieve maximal therapeutic effect, it is 
hypothesised that IUdR should be administered in multiple doses by multiple injections, by 
slow release from biodegradable implants, or by slow-pump delivery.
In previous studies, we observed that IUdR uptake decreased with increasing heterogeneity 
in proliferative activity of tumour cells. T o overcome this treatment problem, we compared 
the toxicities of three radioiodoanalogues of IUdR, [123I]IUdR, [125I]IUdR and [131I]IUdR -
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to the human glioma cell line UVW, cultured as monolayers in exponential and plateau 
phase of growth and as multicellular spheroids using a clonogenic end point. Monolayers 
treated in exponential growth phase were most efficiently sterilised by [125I]IUdR 
(concentration resulting in 37% survival (C37) = 2.36 kBq/ml), while [123I]IUdR and 
[131I]IUdR were less effective eradicators of clonogens (C37 = 9.75 and 18.9 kBq/ml 
respectively). Plateau phase monolayer cultures were marginally more susceptible to 
treatment with [123I]IUdR and [125I]IUdR (40% clonogenic survival) than [131I]IUdR (60% 
clonogenic survival). In cells derived from glioma spheroids, both [125I]IUdR and 
[123I]IUdR were again more effective than [131I]IUdR at concentration up to and including 
20 kBq/ml. However, the survival curve for [131I]IUdR crossed the curves for the other 
agents, resulting in lower survival for [131I]IUdR than [123I]IUdR and [125I]IUdR at 
concentrations of 40 kBq/ml and higher. The clonogenic survival values at 100 kBq/ml 
were 13%, 45% and 28% respectively. It was concluded that IUdR incorporating the 
Auger electron emitters 123I and 125I, killed only cells which were in S phase during the 
period of incubation with radiopharmaceutical, whereas the superior toxicity to clonogenic 
cells in spheroids of [131I]IUdR at higher concentration was due to cross-fire P-irradiation. 
These findings suggest that [13,I]IUdR or combinations of [131I]IUdR and [125I]IUdR or 
[123I]IUdR may be more effective than Auger electron emitters alone for the treatment of 
residual glioma.
202
Future work
1) In chapter 9 we developed radiobiological analyses of DNA-targeted radiotherapy using 
ultra-short-range Auger electron emitters such as 1231, 125I and P-emitting radionuclides such 
as 131I conjugated to IUdR. There are several important findings from this study, including 
the predicted superiority of 125I which has to be targeted to DNA in order to achieve 
optimal cell kill and the cross fire effect of 131I on non-dividing cells. The results obtained 
strongly favour a combined modality approach to Auger electron therapy together with P- 
emitting radionuclides such as131I. The optimal proportion of each radioisotope in such 
cocktails remain to be established.
2) Recently, high specific activity 5-[211At]astato-2'-deoxyuridine ([211At]AUdR) has been 
synthesised and has been shown, like IUdR, to be readily incorporated into cellular DNA. 
However, [211At]AUdR may be 100 times more toxic to clonogenic cells in vitro than 125I 
or 123I[IUdR] (Vaidyanathan et al., 1996). 211At emits high LET a  particles whose range 
is equivalent to a few cell diameters. These characteristics suggest that [211At]AUdR could 
be superior to Auger electron emitters both in terms of tumour cell kill and homogeneity 
of dose distribution. However, the use of [ 21,At]-astatinated radiopharmaceuticals presents 
formidable difficulties in relation to logistics and radiation protection. The strategies in 
which the problems associated with the use of this radiopharmacutical might be minimized 
and the possibilities of maximal therapeutic benefit by use of 'cocktails' of 
radioiodoconjugates of IUdR including both Auger electrons to kill cycling cells and the a- 
emitter [211At]AUdR to eliminate untargeted cells by cross fire must be explored.
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3) The limitation of conventional radiotherapy lies in the fact that it is not tumour specific. 
Targeted radiotherapy seeks to improve biological specificity by conjugation of 
radioisotopes to tumour-seeking agents. However, there are few tumour types for which 
sufficiently selective agents exist and the therapeutic advantage is generally modest 
(Wheldon, 1994). An alternative strategy would be tumour-specific radiosentisation to 
confer biological specificity on radiotherapy, whilst preserving its physical advantages of 
’steerability' and dosimetric precision. Recent developments in molecular radiobiology and 
the availability of viral delivery vectors have raised the possibility that gene therapy 
methodology could be developed as a radiosensitising modality (McBride and Dougherty, 
1995; Kim et al., 1995). Weichselbaum et al. (1994), have described the combination of 
gene therapy and radiation therapy as providing a new paradigm for cancer treatment.
Cell sterilisation by ionising radiation remains incompletely understood at the molecular 
level. Double strand breaks in DNA are certainly implicated but more complex lesions 
may be involved. Some genes have been identified and sequenced whose expression 
appears to have radioprotective effect such as the superoxide dismutase gene (Suresh et al., 
1994), the Ataxia telangiactasia (AT) gene (Dahlberg and Little, 1995) and the Ku gene 
(Ross et al., 1995). The recent sequencing of the AT gene by Savitsky (1995), creates the 
possibility of radiosensitisation by gene inhibition. If gene inhibition could be made 
tumour selective, this could significantly improve the therapeutic ratio in radiotherapy. 
Inhibition could be accomplished by transfecting an 'anti-protector gene' in the form of an 
anti-sense RNA, a gene repressor protein or an inactivator of the protein product of the 
protector gene. The anti-protector gene might be selectively expressed in tumour cells using 
an engineered viral construct as a delivery vehicle under control of a promoter which is 
selectively active in tumour cells or in the tissue from which the tumour is derived. The 
exploration of such novel approaches is a task for future.
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